Connect public, paid and private patent data with Google Patents Public Datasets

Process for the demonstration and determination of reaction components having specific binding affinity for each other

Download PDF

Info

Publication number
US3791932A
US3791932A US3791932DA US3791932A US 3791932 A US3791932 A US 3791932A US 3791932D A US3791932D A US 3791932DA US 3791932 A US3791932 A US 3791932A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
ml
enzyme
hcg
reaction
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
A Schuurs
B Weemen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzona Inc
Original Assignee
Akzona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/543Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/536Immunoassay; Biospecific binding assay with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539Immunoassay; Biospecific binding assay with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541Double or second antibody, i.e. precipitating antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/971Capture of complex after antigen-antibody reaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808Automated or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones
    • Y10S436/818Human chorionic gonadotropin

Abstract

The present invention relates to a process for the determination of a component of the reaction between a specific binding protein and the substance being specifically bound by such a protein comprising reacting the component to be determined with its binding partner in an insolubilized form, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a determined amount of a coupling product of the substance to be determined with an enzyme, and finally determining the enzyme activity of the liquid or solid phase of the reaction mixture obtained.

Description

United States Patent [191 Schuurs et al.

[451 Feb. 12, 1974 [75] Inventors: Antonius Hermanus Wilhelmus Maria Schuurs; Bauke Klaas Van Weemen, both of Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,

22 Filed: Jan. 27, 1972 21 App]. No.: 221,447

[30] Foreign Application Priority Data Feb. 10, 1971 Netherlands 7101728 [52] US. Cl. 195/l03.5 R, 424/12, 23/230 B [51] Int. Cl. G0ln 31/14 [58] Field of Search 195/103.5 R; 23/230 B; 424/12 [56] References Cited UNITED STATES PATENTS 3,654,090 4/1972 Schuurs et al. 195/1035 R Primary Examiner-Alvin E. Tanenholtz Assistant ExaminerMax D. Hensley Attorney, Agent, or Firm--Hugo E. Weisberger [57] ABSTRACT The present invention relates to a process for the determination of a component of the reaction between a specific binding protein and the substance being specifically bound by such a protein comprising reacting the component to be determined with its binding partner in an insolubilized form, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a determined amount of a coupling product of the substance to be determined with an enzyme, and finally determining the enzyme activity of the liquid or solid phase of the reaction mixture obtained.

4 Claims, N0 Drawings PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF REACTION COMPONENTS HAVING SPECIFIC BINDING AFFINITY FOR EACH OTHER For the demonstration and determination of substances playing a prominent part in biochemical processes, i.e. low molecular substances, such as vitamins and steroids, or high molecular ones, such as proteins and carbohydrates, it is often possible to employ reactions of these substances with proteins having a specific binding affinity for these substances. Thus, it is possible to determine the concentration of a steroid by employing a protein capable of binding this steroid specifically. As examples of such combinations are mentioned cortisol and transcortin, l7B-oestradiol and the oestradiol-binding receptor protein of the uterus.

It is also possible to link a low molecular substance chemically with a protein, and to inject this conjugate into a test animal, which then reacts by forming antibodies against, among others, the low molecular substance. The latter is in this case to be regarded as a socalled hapten. The antibodies against the hapten may be regarded as a special case of specific binding proteins.

High molecular substances, such as simple and conjugated proteins and carbohydrates, are capable of causing the formation of antibodies on being injected into animals in the correct experimental conditions. Between these antibodies and the injected high molecular substance, the antigen, there is again question of specific binding affinity.

Determination methods in which these specific binding affinities are employed, are often based on the competition between the substance to be determined in the sample and the known quantity of the same substance, labelled radioactive, for a limited quantity of its binding partner. The quantity of substance to be determined determines what part of the radioactive labelled substance can be bound by its binding partner. It is also possible to determine an unknown quantity of specific binding protein by reacting a sample of it with a certain quantity of radioactive labelled, specific binding substance. The terms by which these methods are designated in the literature, depend upon the nature of the specific binding protein. They speak of competitive protein binding assays, where receptor or transport proteins are used, and of"radioimmunological determinations" where antibodies are employed as specificbinding protein.

Instead of labelling one of the components of the above-described reactions with a radioactive isotope, it is also possible to employ an enzyme as a labelling substance. Where use is made of the binding affinity between a low molecular substance and its specif c binding protein, the low molecular substance can be coupled with an enzyme. The coupling product, low molecular substance/enzyme, can then be used in experimental set-ups as described above. Where use is made of the binding affinity between an antigen and its antibody, the antigen may, for example, be coupled with an enzyme instead of labelling it with a radioactive isotope as is conventional in radioimmunological methods.

For all the methods in which such a labelled reaction component is employed, a suitable method for separating the free labelled compound attached to the binding partner, is essential. Dependent upon the nature of the substances participating in the reaction, various separation methods can be employed, for example electrophoresis, gel filtration, selective adsorption, application of one of the reaction components in an insolubilised form, and application of antibodies against one of the reaction components, also in an insolubilised form.

In spite of the high sensitivity that can be achieved by these methods, it is not always possible to demonstrate or determine substances occurring in extremely low concentrations in, for example, serum or urine. Thus, it is very difficult and often impossible to demonstrate adrenocorticotrophic hormone (ACTH) by a radioimmunological method, unless one has the disposal of a very rare antiserum containing antisubstances with an extremely high binding affinity for ACTH.

Also determinations of smaller peptide hormones such as oxytocin in non-extracted serum, causes great difficulties, because the required sensitivity cannot be reached.

Although, in principle, the immunological crossreaction between HCG and LH enables both hormones to be determined with one test-system, most methods for the determination of human chorionic gonadotrophin (HCG) by a coupling product of HCG and an enzyme cannot be used for the demonstration and determination of luteinizing hormone (LH). This is due to the fact that LH occurs in much lower concentrations in blood and urine than HCG during pregnancy, so that the sensitivity of the test systems are insufficient. This shortage of sensitivity can be decreased by extracting the substance to be determined from the medium in which it occurs or by concentrating the medium. These methods, however, are very laborious, and the results often unsatisfactory.

A process has now been found for the demonstration and determination of a component of the reaction between specific binding proteins and the substances that can be specifically bound by these proteins, using the known binding affinity of such components for each other, which comprises reacting the component to be determined with its binding partner, which has been or is insolubilised, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a coupling product, obtained by binding a substance capable of reacting specifically with one of the reaction components, to an enzyme, and finally determining the enzyme activity of the liquid or the solid phase in the reaction mixture obtained, which is a measure for the quantity of the substance to be determined.

The binding partner required for the determination of the component present in an unknown quantity, is employed in an insoluble form. The determination can take place by adding the binding partner to the reaction mixture in an insoluble form and reacting the mixture in a heterogeneous medium, but the binding partner can also be added in a dissolved form, after which it can be insolubilised by adding antisubstances against it.

The substance capable of reacting specifically with one of the reaction components, and which is employed coupled with an enzyme, may be the other reaction component, but also a third substance that must possess a specific affinity for one of the components of the reaction.

The method can be applied to the various reaction systems described above, i.e. antigen/antibody, hapten- /antibody and a low molecular substance/specific binding protein. As third substance a second antibody may occur, that is to say, an antibody against the gammaglobulin fraction of the species of animal in which the first antibodies have been generated. This situation may occur in the systems antigen/(first) antibody and hapten/(first) antibody. As third substance may also occur an antibody against a specific binding protein.

The essence of the method is the performance in two steps, in between which a separation takes place of the liquid and the solid phase of the reaction mixture. With the solid phase the second step is performed. Only in this stage the enzyme coupling product is employed and the enzyme activity determined.

The most important advantages of the method found are:

l. the first step can be performed in a larger volume than is desirable or possible for the second step. This is of great importance when the substance to be determined occurs in too low concentrations to be determined by known methods.

2. In the liquid to be examined substances may be present influencing the reactions in the second step unfavourably. Especially the enzyme present in the coupling product and the enzymatic catalysing reaction may be sensitive to disturbing substances in the test liquid.

The method found can especially be employed for the determination of substances present in body liquids such as hormones, their antibodies and specific binding proteins, as well as enzymes. Also factors of bloodclotting, fibrinolysis and complement systems, pathological proteins in body liquids, as well as antibodies against pathogenic microorganisms and iso-antibodies can be determined in this manner.

The medium in which the first step of the determination takes place often consists for a large part of test liquid, such as urine or serum. If considered necessary, it can be adjusted to the pH required for the immunochemical reaction, viz. between 5 and 9, by adding a dry buffer salt or a small volume of a concentrated buffer solution. The medium of the second step is also a buffer of a pH required for the immunochemical reaction. For this purpose phosphate buffers, citrate buffers, tris(hydroxy methyl)-aminomethane, and imidazole buffers can be employed. It may be necessary to use for the relative enzyme reaction a buffer of another composition and pH, which depends upon the enzyme employed.

The manufacture of the insolubilised reaction component can take place in various manners, i.a. dependent upon the properties of this reaction component. Thus, antibodies, specific binding proteins and proteinlike antigen can be insolubilised by cross-linking, for example, glutaric aldehyde and chloroformic acid ethyl ester, by physical adsorption or chemical coupling with an insoluble carrier, such as cellulose compounds, agarose, cross-linked dextran, polystyrene and the like, or by coupling with antibodies against the relative protein coupled with an insoluble carrier. Low molecular substances can be bound by methods dependent upon the structure of the low molecular substance and the carrier material. Some of the low molecular substances may already possess groups capable of reacting with the reactive parts on the carrier material: in other cases such groups will have to be introduced by organic chemical reactions.

The manufacture of the enzyme coupling products is also performed by methods dependent upon the properties of the molecules incorporated into the coupling product. A covalent bond of proteins to enzymes can be effected by reagents such as carbodiimides, diisocyanates, glutaric aldehyde and bis-diazobenzidine. The coupling of low molecular substances can take place in various manners. Some of these substances may already possess groups that can be cross-linked with reactive groups of the enzyme; in other cases such groups will have to be introduced by organic chemical reactions. It stands to reason that in the manufacture of these coupling products the original binding properties of the substances bound to the enzyme may not change very much; no more may the enzyme activity be decreased considerably.

The choice of the enzyme that is to form a part of the coupling product, is determined by properties such as the specific binding activity (a high conversion rate raises the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme catalysing a conversion in which coloured reaction components are involved, is simple. Such colorimetric determinations can be automated in a simple manner.

According to the invention it is also possible to employ enzymes catalysing those conversions in which reaction components are involved that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automated.

In the manufacture of the coupling products enzymes such as catalase, peroxidase, B-glucuronidase, B-B- glucosidase, ,B-D-galactosidase, urease, glucoseoxidase and galactose-oxidase are preferred, especially the group of the oxidoreductases.

The determinations according to the invention are broadly performed as follows: A certain volume of a test liquid, for example 10 ml, containing a very low concentration of the component to be determined, is mixed with a certain quantity of an insolubilised reaction partner of the substance to be determined. The test liquid may be urine, in which the component to be determined occurs in low concentration, or serum, which has been diluted to diminish the influence of disturbing factors. In order to enable the reaction to be performed in the heterogeneous system, the mixture is agitated. The resulting solid phase is separated from the test liquid, for example by centrifugation, and washed, if considered necessary. The first part of the determination can also be performed by incubating the test liquid with a certain quantity of the reaction partner of the substance to be determined in a dissolved form, after which a quantity of insolubilised antibody against that reaction partner is added and the mixture agitated and finally centrifuged. Separation by filtration and decantation is also possible.

The second part of the determination is performed by resuspending the insoluble substance, which forms the The enzyme activity of a phase of the reaction mixture is demonstrated or measured by incubating that phase with a substrate and other substances required for the relative enzyme reaction.

Preferably a reaction is employed in which a coloured compound is formed, or removed, whose adsorption can be easily quantitatively determined.

The form in which the reagents can be used are manifold. The component of the reaction system coupled with an enzyme may have been dissolved in a buffer, or freeze-dried. Also a solid carrier can be used, for example a strip of paper impregnated with the enzyme coupling product.

The insoluble component can be processed in the form of particles of various sizes, such as grains, plates and rods, or in the form of a strip of some or other carrier material.

For the performance of the process according to the invention a test-pack is usually employed, chiefly consisting of:

a. a certain quantity of the enzyme coupling product;

b. a corresponding quantity of one of the components of the reaction system in an insoluble form;

c. a substrate for the determination of the quantity of the enzyme employed.

The test-pack can contain the necessary auxiliaries, if required, to make a dilution series of the sample to be tested for a quantitative determination, such as test tubes, pipettes and flasks containing a diluent. For the determination of antigens or haptens, or their antibodies, the test-pack contains at least:

a. a certain quantity of the coupling product of the antigen or hapten, or an antibody against it, and an enzyme;

b. a corresponding quantity of an insolubilised component of the reaction system antigen/antibody, or hapten/antibody, and

c. a substrate for the determination of the enzyme activity.

The invention is further illustrated by the following examples, which are on no account intended to limit the invention.

EXAMPLE I Determination of human chorionic gonadotrophin (HCG) in serum.

a. Preparation of HCG-HRP. Five mg of HCG and 20 mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.2. After 40 u/ltr of 25 percent glutaric aldehyde solution had been added, the mixture was shaken at room temperature for 2 hours. Then the mixture was centrifuged for 5 minutes at 250 g, after which it was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.2. The fractions whose highest percentage of enzyme activity was bound by antibodies against HCG, were used in the test system.

b. Preparation of antibodies against HCG. Antibodies against HCG were generated in rabbits as described by Schuurs et. al. in Acta Endocr. (Kbh.) 59, (1968).

c. Preparation of the immuno-adsorbent, anti-HCG- cellulose. The y-globulin fraction of the anti-HCG- serum described under 1)) was prepared by precipitation with 18 percent (w/v) solid Na SO The precipitate was washed and then taken up in so much 0.05 M borate buffer of pH 8.6 that the ultimate protein concentration was 10 mg/ml. M-aminobenzyloxy methyl cellulose (350 mg) prepared by Gurvichs method, described in Biokhimiya 26, 934 (1961 was suspended in 50 ml of distilled water and diazotized by adding 10 ml of 36 percent hydrochloric acid and, dropwise, 10 ml of 10 percent NaNo -solution. The suspension was centrifuged and washed, and the precipitate resuspended in 43 ml of 0.05 M sodium borate of pH 8.6. 'yglobulin solution prepared 7 ml were added to this suspension. The mixture was stirred for 26 hours at 4C, centrifuged, and finally washed with 1 ltr of 0.02 M phosphate buffer of pH W V p 7 d. 'otr'ni'ifififiafimofi serum. A dilution series of HCG (8-4-2-l-0.5-0.25-0 l.U./ml) was prepared with a dilution liquid consisting of one part of mans serum and 2 part of 0.05 M phosphate buffer of pH 6.2. Of each of the thus prepared HCG dilutions 0.5 ml was rotated for 2 hours at room temperature with 0.5 ml of the immuno-adsorbent suspension (4 mg/ml), prepared in accordance with c), and then centrifuged. The precipitate was washed twice, each time with 2 ml of 0.05 M phosphate buffer of pH 6.2. The precipitate was mixed with 1.0 ml of HCG-HRP solution in a suitable dilution, as well as in 0.05 M phosphate buffer of pH 6.2, and rotated again at room temperature for 2 hours.

After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of a substrate solution consisting of 10 ul of 30% H 0 and 20 mg of 5-amino salicylic acid in ml of0.02 M phosphate buffer of pH 6.0. After 30 minutes the extinction was measured at 460 nm.

In the test system described a HCG concentration of 0.25 I.U./ml caused a measurable increase in the enzyme activity in the supernatant liquid, while a concentration of 1 I.U./ml caused the maximum increase. in this test the centrifugation step proved to be of decisive significance, as omission of this step gave rise to wrong measuring results of the enzyme activity, La. owing to turbidity of the serum and the peroxidase-like activity of it.

The HCG content of serum of pregnant women could be determined in this experimental set-up provided that the serum sample was diluted in the ratio of at least 1:3.

EXAMPLE II Determination of HCG in low concentrations by means of an enzyme/antigen coupling product.

a. Preparation of antisubstances against rabbit-yglobulin. Rabbit-y-globulin was isolated from normal rabbit serum by precipitating it with 18 percent (w/v) solid Na SO Antibodies against it were generated in a sheep. The injection scheme was:

Day Quantity Freunds adjuvant Manner of injection 0.5 mg lntramuscularly 14 0.5 mg Do.

28 1 mg Do.

42 1 mg Intravenously 56 1 mg Do.

On day 70 the sheep was exsanguinated.

b. Preparation of [sheep-anti-(rabbit-'y-globulin)]- cellulose. The 'y-globulin fraction of the sheep serum described under a) was prepared by precipitating it with 16 percent (w/v) solid sodium sulphate. This y-globulin fraction was bound to maminobenzyloxymethyl-cellulose, as described in example I c).

c. Determination of human chorionic gonadotrophin (HCG). A dilution series of HCG was prepared in 0.01 M phosphate buffer of pH 6.0, which also contained 2 percent (v/v) normal sheep serum. The dilution series was in the range of 10 to 320 I.U./ l, the dilution factor being 2. v

To 5 ml of a HCG solution was added 0.1 ml of a rabbit (anti-HCG) serum (see example I b), diluted with the same buffer to the desired strength. The mixture was left to stand at room temperature for 30 minutes, after which 1.5 mg of [sheep-anti(rabbit-y-globulin)] cellulose were added and the mixture was rotated for 2 hours.

The cellulose was centrifuged for minutes at 3,000 rpm. and resuspended in 1 ml of a solution of HCG- l-IRP coupling product, prepared in accordance with example I a), diluted to the desired strength with 0.01 M phosphate buffer of pH 6.0 with 2 percent normal sheep serum. The mixture was stirred again for 2 hours. After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 m] of it to 1.5 ml of enzyme substrate consisting of 10 pl of 30 percent H 0 and 20 mg of 5-amino-salicylic acid in 150 ml of 0.01 M phosphate buffer of pH 6.0. The mixture was left to stand for 30 minutes at 25, after which the extinction was measured at 460 nm. In the supernatant liquid 100 percent enzyme activity is measured provided that no anti-HCG serum is added to the system.

A dilution series of HCG, prepared with childrens urine as dilution liquid, gave an identical pattern so that also measurings in urine samples can be performed.

The centrifugation step effects a ten times higher sensitivity than can be reached in a system without centrifugation.

EXAMPLE III Determination of HCG and LH in low concentrations by means of an enzyme/antibody coupling product.

a. Preparation of the immune-adsorbent HCG cellulose. This immuno-adsorbent was prepared by the method mentioned in example I c), but instead of rabbit-y-globulin, 100 mg of HCG were coupled to 500 mg of m-aminobenzyloxymethyl cellulose.

b. Purification of antibodies against HCG. Ten ml of rabbit-anti-HCG serum, prepared in accordance with example I b), was diluted with 90 ml of 0.05 M citrate of pH 5.0 and slowly led over the immuno-adsorbent, which has packed in a column and mixed with 10 parts of Sephadex G-25. The immunoadsorbent was washed with the same buffer till no more protein was eluted. The antisubstances were eluted with 0.05 M citrate of pH 2.0. The fractions were collected in one half volume of 0.25 M NaHCO;,, tested for their content of antibodies and protein, and the suitable fractions were frozen.

c. Preparation of the coupling product (anti-HCG)- HRP. Twenty mg of horse radish peroxidase (HRP) were dissolved in 2 ml of an antibody solution having a protein content of 2 mg/ml. To this solution were added 8 pl of 25 percent glutaric aldehyde solution, after which the mixture was shaken for 2 hours at room temperature. Finally the mixture was fractionated over a Sephadex G-200 column in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme activity were bound to HCG cellulose, were used in the test system.

d. Determination of HCG and LH. Ten ml of a HCG dilution series of HCG and 10 ml ofa HCG dilution series of LH were mixed with 5 mg of anti-HCG cellulose, prepared in accordance with example I c), which was suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, and the mixtures rotate at room temperature for 2 hours. The immunoadsorbent was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0.

To the immuno-adsorbent 1 ml of the (anti-HCG)- HRP coupling product was added in the desired dilution, after which the mixture was rotated again for 2 hours. Finally, after centrifugation, the enzyme activity of the supernatant liquid was determined as described in the previous examples.

By this method a concentration of from 5 to 10 I.U. of HCG and 10 to 20 I.U. of LH per litre respectively could be determined. If the centrifugation step is omitted the optimum sample size is 0.5 nl and the sensitivity about I.U. of HCG per litre, or about 200 I.U. of LH per litre, so that the method according to the invention yields a 10-20 fold increase in sensitivity.

EXAMPLE IV Determination of HCG and anti-HCG.

a. Rabbit-serum was fractionated over DEAE cellulose in accordance with the prescription of H.A. Sober and others in J. Am. Chem. Soc. 78, 756 (1956). The isolated y-globulin fraction, which was immuno-electrophoretically pure, was partly used for generating antibodies in a sheep in accordance with the scheme of example [I a), while besides 100 mg of rabbit-y-globulin was coupled to 500 mg of m-aminobenzyloxymethyl cellulose by the method described in example I c).

From the sheep [anti-(rabbit-y-y-globulin)] serum prepared the specific antibodies were isolated by the method described in example II b) with the immune-adsorbent III b. The coupling product [anti-(rabbit-y-globulinH- HRP was prepared analogous to the coupling product (anti-HCG)-HRP, described in example lll c).

0. Determination of anti-HCG. A dilution series of rabbit-(anti-HCG) serum was prepared with 0.05 M phosphate buffer of pH 6.0.

Rabbit-(anti-HCG) serum (0.5 ml) was rotated with 0.25 mg of HCG-cellulose for 2 hours (see example 111 a). The reaction mixture was centrifuged and the precipitate washed four times with phosphate buffer, each time with 3 ml, after which the precipitate was resuspended in 1 ml of a solution of the coupling product b. The mixture obtained was again rotated for 2 hours. After centrifugation the enzyme activity in the supernatant liquid was determined, as described in example l d).

d. Determination of HCG. With the reagents prepared, HCG was determined by incubating solutions of it with 0.5 ml of rabbit-(anti-HCG)-serum in a dilution which in the system described under just causes an almost maximum reduction in enzyme activity in the supernatant liquid, and performing the process described under c) with the mixture obtained.

Where use was made of ml of HCG solution, it

proved to be possible to demonstrate concentrations of about 1.U./l of HCG.

EXAMPLE v Determination of insulin in serum.

a. Preparation of insulin-(glucose-oxidase). Five mg of hog insulin and 25 ml of glucose-oxidase were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.5. To this solution 5 'yl of 25 percent glutaraldehyde solution were added, after which the mixture was shaken at room temperature for 90 minutes. The mixture was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme ac tivity could be bound by antibodies against insulin were used in the test system.

b. Preparation of antibodies against insulin. Ten caviae were injected intramuscularly, once a week, with 1 mg of hog insulin in complete Freunds adjuvant, over a period of from 4 to 8 weeks. After having been left alone for 2 weeks the animals were injected intravenously with another milligram of insulin without adjuvant. Another 2 weeks later the animals were exsanguinated. Hypoglycemia occurring occasionally was combated by intraperitoneal administration of glucose.

c. Preparation of anti-substances against cavia 'y-globulin. Cavia -y-globulin was prepared by adding one volume of a saturated ammonium sulphate solution to two volumes of cavia serum. The resulting precipitate was washed twice with 33 percent saturated (NH S0 solution and then taken up in a physiological salt solution. A sheep was immunized with increasing dosages of the 'y-globulin prepared, viz. 0, 5, 1 and 2 mg. The injections were given every 2 weeks, the immunogen being mixed with complete Freunds adjuvant. Two weeks after the last injection another 2 mg of y-globulin, in a physiological salt solution, were given. One week later the animal was exsanguinated.

d. Preparation of insoluble antibodies against cavia 'y-globulin. Ten gm of microcrystalline cellulose were activated by adding it, while stirring, to 400 ml of 2.5 percent (w/v) CNBr solution, after which the pH was adjusted to 10.5 with an 1 N NaOH- solution, and it was maintained at it for 2 minutes. The cellulose was washed with ice water and with 0.1 M NaHCO;,. To 10 ml of sheep-anti-(cavia y-globulin) serum 1.6 gm of NaSO, were added. After stirring for 1 hour at room temperature the precipitate was centrifuged, washed twice with 20 ml of 16 percent (w/v) Na SO. solution, and finally taken up in 10 ml of 0.1 M NaHCO;,.

The activated cellulose was mixed with 40 ml ofa 0.1

M NaHCO;, solution and the 10 ml of y-globulin solution. This suspension was rotated for 40 hours at 4C and washed, twice with 5 ml of 0.5 M NaHCO twice with 500 ml of 0.05 M citrate of pH 1.1, and two times with 500 ml of 0.05 M phosphate of pH 6.2.

e. Determination of insulin in serum. Four ml of an insulin dilution series in the range of from O-lOO ng/ml, were incubated at room temperature, for 4 hours, with 1.0 ml ofanti-insulin serum (with 0.15 M phosphate buffer of pH 6.0, diluted to the desired strength). After that 5 mg of the immunoadsorbent prepared under a), suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, were added, and the resulting mixture rotated overnight at 4C. Then the immuno-adsorbent was centrifuged and washed three times with 5 ml of 0.05 M phosphate buffer of pH 6.0 (each time with 5 ml), to which 2 percent sheep serum had been added. After that 1.0 ml of insulin-glucose oxidase, diluted to the desired strength with the wash buffer, was added to the immunoadsorbent. The mixture obtained was again rotated overnight and centrifuged, after which the enzyme activity in the supernatant liquid was measured by incubating 0.5 ml of it with 2.5 ml of a substrate solution, and the extinction measured at 460 nm. The substrate solution contained mg of glucose, 10 ugm of peroxidase and 1 mg of S-aminosalicylic acid per 2.5 ml of 0.05 M phosphate buffer of pH 6.0.

The centrifugation step, in this case serving both to raise the maximum volume of the test liquid to be employed and to remove serum factors disturbing the reaction, caused a lO-fold increase in sensitivity, so that a concentration of a few ng/ml of insulin could be demonstrated.

EXAMPLE VI Determination of oestradiol.

a. Preparation of oestradiol-l7-succinyl-l-1RP. Fifty mg of oestradiol-l7-haemisuccinate and 0.08 ml of tri-n-butylamine were dissolved in 2.5 ml of diox ane. To the cold solution (2C) 15 u] of isobutylchlorocarbonate were added. After 30 minutes this solution was mixed with mg of horse radish peroxidase (HRP) in 7.5 ml of a mixture of dioxane and water (2:3), which had been adjusted to pH 9.5 with caustic soda. This solution was stirred for 4 hours at 2C, after which it was dialysed for 18 hours. The precipitate obtained after the pH of the dialysate had been adjusted to 4.6 was centrifuged, washed, and taken up in 5 ml of distilled water, which had been adjusted to pH 8. The material was purified further by precipitating it twice with 10 ml of acetone. The ultimate product was taken up in 10 ml of 0.05 M phosphate buffer of pH 7.8.

b. Preparation of oestradiol-l7-succinyl-BSA. The preparation was prepared by the mixed anhydride method as described under a). The starting material was 100 mg of oestradiol-l7-haemisuccinate and mg of bovine serum albumin (BSA).

0. Preparation of anti-substances against oestradiol. A sheep was injected every 4 weeks with 4 mg of oestradiol-l7-succinyl-BSA in complete Freunds adjavant. With regular intervals blood was taken from the sheep. The serum was adsorbed with BSA.

Day Quantity Freund's adjuvant Manner of injection 200 ugm lntramuscularly 14 400 ugm Do.

28 800 tgm Do.

42 800 agm lntravenously Two weeks after the last injection the animals were exsanguinated.

e. Preparation of the immuno-adsorbent [rabbitanti(-sheep-y-globulin)] cellulose.

The 'y-globulin fraction of the anti-sera described under 12) was prepared by precipitation with 18 percent w/v Na SO The product obtained was coupled with cellulose by Gurvichs method described in example I c).

f. Determination of oestradiol. A dilution series of oestradiol (00.5124-8l6 ng/ml) was prepared in phisphate buffer of pH 6.0. Five ml of sample were mixed with 0.5 ml of the sheep-antioestradiol-serum in the desired dilution. After incubating the mixture for 2 hours at room temperature 1 ml of immunoadsorbent suspension (see e) of 60 mg/ml was added, after which the mixture was rotated for 4 hours at room temperature. The cellulose was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0 containing 2 percent BSA. Then 1 ml of oestradiol-17-succinyl- HRP, diluted to the desired strength with the buffer with which the mixture was washed, was added to the cellulose. The mixture was rotated for 1 hour, after which it was centrifuged again and the enzyme activity in the supernatant liquid was measured as described in example I.

By the method described concentrations of 1 ng/ml of oestradiol could be demonstrated, which means an increase in sensitivity by a factor 10, compared with the test without centrifugation step.

EXAMPLE Vll Determination of cortisol.

a. Preparation of cortisol-21-galactose-oxidase.

Fifty mg of cortisol-2l-haemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride method as described in example VI a).

b. Preparation of insoluble transcortine. One hundred mg of transcortine purified by DEAE cellulose chromatography, followed by hydroxylapatite chromatography, were coupled with 3 gm of Sepharose 4B by the CNBr method: Sepharose 4B suspension (3 gm) was activated by mixing it with 4 ml of 2.5 percent (w/v) CNBr-solution in distilled water, after which the pH was adjusted to 1 N NaOH between 10 and 11, at which value it was maintained for 6 minutes. Then the Sepharose was washed with ice-water and with 0.1 M NaHCO;,, after which mg of transcortine in 20 ml 0g 0.1 M NaHCO:, were added, and the suspension was shaken at 4C for 24 hours, After being washed successively with 0.5 M NaHCO;,, 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer, to which 0.1 percent merthiolate had been added.

0. Determination of cortisol. A cortisol dilution series, in the range of from 0.25-16 ng/ml was prepared in 0.05 M phosphate buffer of pH 6.0. File ml of each cortisol solution (in 0.5 M phosphate buffer of pH 6.0) were rotated overnight with 5 mg of transcortine-Sepharose, at 4C. After centrifugation 1 ml of cortisol-2l-galactose oxidase solution, diluted to a suitable concentration in the buffer mentioned before, was added, after which the mixture was rotated for 2 hours at 4C. After recentrifugation the enzyme activity in the supernatant liquid was determined by adding 0.5 ml of it to 1.5 ml of substrate constisting of 100 mg of D- galactose, 20 mg of S-amino-salicylic acid and 10 ugm of peroxidase in ml of 0.02 M phosphate buffer of pH 6.0. Finally, after 30 minutes, the extinction was measured at 460 nm.

By this method about 1 ng/ml cortisol could be demonstrated, which means an increase in sensitivity by a factor 10.

We claim:

1. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:

a. providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form;

b. reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase;

c. separating the solid phase from the liquid phase;

d. adding to said solid phase a given quantity of a coupling product of the component to be determined with an enzyme; and

e. determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.

2. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:

a. providing a given quantity of the binding partner of the component to be determined in a soluble form;

b. adding a given quantity of an antibody against said binding partner, which antibody is in an insoluble 14 sure of the quantity of the reaction component to be determined.

3. The process of claim 1 in which the enzyme is an oxido-reductase.

4. The process of claim 2 in which the enzyme is an oxido-reductase.

Claims (3)

  1. 2. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of: a. providing a given quantity of the binding partner of the component to be determined in a soluble form; b. adding a given quantity of an antibody against said binding partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase; c. separating the solid phase from the liquid phase; d. adding to said solid phase a given quantity of a coupling product of the component to be determined with an enzyme; and e. determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined.
  2. 3. The process of claim 1 in which the enzyme is an oxido-reductase.
  3. 4. The process of claim 2 in which the enzyme is an oxido-reductase.
US3791932A 1971-02-10 1972-01-27 Process for the demonstration and determination of reaction components having specific binding affinity for each other Expired - Lifetime US3791932A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL7101728A NL154600B (en) 1971-02-10 1971-02-10 Method for the detection and determination of specific binding proteins and their corresponding bindable substances.

Publications (1)

Publication Number Publication Date
US3791932A true US3791932A (en) 1974-02-12

Family

ID=19812444

Family Applications (1)

Application Number Title Priority Date Filing Date
US3791932A Expired - Lifetime US3791932A (en) 1971-02-10 1972-01-27 Process for the demonstration and determination of reaction components having specific binding affinity for each other

Country Status (11)

Country Link
US (1) US3791932A (en)
JP (1) JPS5247011B1 (en)
BE (1) BE779209A (en)
CA (2) CA958314A (en)
DE (1) DE2206103B2 (en)
DK (1) DK150170C (en)
ES (1) ES399608A1 (en)
FI (1) FI53894C (en)
FR (1) FR2126760A5 (en)
GB (1) GB1363565A (en)
NL (1) NL154600B (en)

Cited By (648)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875011A (en) * 1972-11-06 1975-04-01 Syva Co Enzyme immunoassays with glucose-6-phosphate dehydrogenase
US3904367A (en) * 1973-08-15 1975-09-09 Gen Electric Contrast enhancement for immunological film detection
US3951748A (en) * 1974-11-11 1976-04-20 Medical Products, Inc. Sensitized matrix for detection of disease
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
DE2643829A1 (en) * 1975-09-29 1977-04-14 Cordis Corp A method for detecting the presence of hepatitis attributable antigens
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
FR2367286A1 (en) * 1976-10-07 1978-05-05 Mochida Pharm Co Ltd New process and immunochemical assay reagents physiologically active substances
US4116776A (en) * 1976-04-19 1978-09-26 International Radioimmune Systems, Inc. Diagnostic blood test and kit for detecting human chorionic gonadotropin
US4200508A (en) * 1977-02-09 1980-04-29 Hidematsu Hirai Method and composition for detecting antigenic substances
US4203802A (en) * 1971-05-14 1980-05-20 Syva Company Inhibitable enzyme amplification assay
WO1980002747A1 (en) * 1979-05-31 1980-12-11 Rapidex Ltd Ultrasensitive enzymatic radioimmunoassay method
US4240751A (en) * 1978-11-09 1980-12-23 Akzona Incorporated Method and apparatus for specific binding substances
US4254223A (en) * 1978-04-18 1981-03-03 Akzona Incorporated Apparatus for colorimetric determination
US4269938A (en) * 1979-03-08 1981-05-26 Eastman Kodak Company Assay of peroxidatively active materials
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
WO1981002792A1 (en) * 1980-03-20 1981-10-01 Res Triangle Inst Detection of antibiotics in milk
US4302534A (en) * 1977-03-16 1981-11-24 Israel Institute For Biological Research Chemiluminescent enzyme immunoassay
US4318707A (en) * 1978-11-24 1982-03-09 Syva Company Macromolecular fluorescent quencher particle in specific receptor assays
US4323647A (en) * 1980-10-15 1982-04-06 University Of Miami Steric hindrance enzyme immunoassay
US4331444A (en) * 1979-03-01 1982-05-25 Fuji Photo Film Co., Ltd. Competitive immunoassay using silver halide fogging agent
US4337063A (en) * 1979-03-01 1982-06-29 Fuji Photo Film Co., Ltd. Competitive immunoassay using spectral sensitizer label
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
WO1982002601A1 (en) * 1981-01-23 1982-08-05 Hospital Supply Corp American Solid phase system for ligand assay
US4343896A (en) * 1975-02-01 1982-08-10 Akzona Incorporated Method and test pack for the demonstration and determination of an antigen or antibody
EP0060700A1 (en) * 1981-03-13 1982-09-22 Immuno-Mycologics, Inc. Assay method and device
US4362531A (en) * 1980-04-15 1982-12-07 Technicon Instruments Corporation Agglutination immunoassays carried out with agent to reduce non-specific interferences
US4374925A (en) * 1978-11-24 1983-02-22 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1983000877A1 (en) * 1981-08-31 1983-03-17 Icl Scient Glucose oxidase immunohistochemical detection of antinuclear antibodies
US4446232A (en) * 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US4446238A (en) * 1981-03-19 1984-05-01 Janssen Pharmaceutica N.V. Bright field light microscopic method of localizing tissue antigens
US4452886A (en) * 1981-09-21 1984-06-05 Henry Robert P Novel photon absorbing or emitting polymers and their use as reagents in immunoassay systems
US4469787A (en) * 1982-05-14 1984-09-04 Mallinckrodt Inc. Immunoassay involving soluble complex of second antibody and labeled binding protein
US4474878A (en) * 1975-09-29 1984-10-02 Cordis Laboratories, Inc. Sandwich EIA for antigen associated with hepatitis
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4503143A (en) * 1982-08-20 1985-03-05 Btc Diagnostics Limited Partnership Enzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
WO1985002260A1 (en) * 1983-11-08 1985-05-23 Quidel Rapid plunger immunoassay method and apparatus
US4530900A (en) * 1982-09-13 1985-07-23 Seragen Diagnostics Inc. Soluble insoluble polymers in enzymeimmunoassay
WO1985003950A1 (en) * 1984-03-08 1985-09-12 Scripps Clinic And Research Foundation A sv40 expression vector containing hbxag as an expression marker
WO1985004397A1 (en) 1984-03-23 1985-10-10 Oncogen Platelet related growth regulator
US4592995A (en) * 1981-03-30 1986-06-03 Dainippon Pharmaceutical Co., Ltd. Reagent for streptococcal anti-esterase assay
US4604365A (en) * 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
US4642285A (en) * 1975-09-29 1987-02-10 Diamedix Corporation Sandwich EIA for antigen
US4665020A (en) * 1984-05-30 1987-05-12 United States Department Of Energy Flow cytometer measurement of binding assays
US4713347A (en) * 1985-01-14 1987-12-15 Sensor Diagnostics, Inc. Measurement of ligand/anti-ligand interactions using bulk conductance
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4753875A (en) * 1981-11-02 1988-06-28 Ryan James W Method for assaying proteases with tagged proteinaceous inhibitors
US4808522A (en) * 1986-04-24 1989-02-28 Moskovsky Gosudarstvennx Universitet Imeni M. V. Lomonoso VA Enzyme immunoassays using inorganic pyrophosphatase
US4812395A (en) * 1984-11-05 1989-03-14 E. I. Du Pont De Nemours And Company Method for detecting enzymatic activity using particle agglutination
US4812396A (en) * 1984-11-05 1989-03-14 E. I. Du Pont De Nemours And Company Method for detecting enzymatic activity using particle agglutination
US4824784A (en) * 1985-04-08 1989-04-25 Hygeia Sciences, Incorporated Chromogenic solution for immunoassay
US4868108A (en) * 1985-12-12 1989-09-19 Hygeia Sciences, Incorporated Multiple-antibody detection of antigen
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US5047330A (en) * 1983-08-17 1991-09-10 Commissariat A L'energie Atomique Compound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5328828A (en) * 1988-12-23 1994-07-12 Syntex (U.S.A.) Inc. Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
US5334513A (en) * 1988-05-17 1994-08-02 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US5468647A (en) * 1988-05-17 1995-11-21 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
WO1997005886A1 (en) * 1995-08-04 1997-02-20 Board Of Regents, The University Of Texas System Compositions for conferring immunogenicity to a peptide
US5610077A (en) * 1980-06-20 1997-03-11 Unilever Patent Holdings B.V. Processes and apparatus for carrying out specific binding assays
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5672475A (en) * 1993-05-06 1997-09-30 Chiron Diagnostics Corporation Mixed luminescent conjugate test
US5698686A (en) * 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US5726015A (en) * 1991-05-15 1998-03-10 Vanderbilt University Method to determine metastatic potential of tumor cells
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5837535A (en) * 1994-06-13 1998-11-17 Henry Ford Health System Neuronal-neonatal gene: neuronatin
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US5858661A (en) * 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US6187563B1 (en) 1998-08-07 2001-02-13 Yale University βIV-spectrin-polypeptides and nucleic acids encoding same
US6284496B1 (en) 1997-10-03 2001-09-04 University Of South Florida DNA vector for determining the presence of out-of-reading-frame mutations
US6312901B2 (en) 1996-07-08 2001-11-06 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US6331275B1 (en) 1996-07-08 2001-12-18 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US6342349B1 (en) 1996-07-08 2002-01-29 Burstein Technologies, Inc. Optical disk-based assay devices and methods
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
US6391563B1 (en) 1980-07-28 2002-05-21 Akzo Nobel N.V. Method for the determination of antigens with the aid of three or more monoclonal antibodies
WO2002044736A2 (en) 2000-11-30 2002-06-06 Molecular Skincare Limited Diagnosis and treatment of epidermal or skin diseases
US6406920B1 (en) 1980-06-20 2002-06-18 Inverness Medical Switzerland Gmbh Processes and apparatus for carrying out specific binding assays
US20020106661A1 (en) * 1996-07-08 2002-08-08 Burstein Laboratories, Inc. Optical disk-based assay devices and methods
US6440682B1 (en) * 1999-05-28 2002-08-27 Detroit R&D Inc. Detection of hypertension using immunoreactive metabolic products
US20020142287A1 (en) * 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
US6482389B1 (en) 1997-10-17 2002-11-19 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
US20020172980A1 (en) * 2000-11-27 2002-11-21 Phan Brigitte Chau Methods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20030003464A1 (en) * 2000-11-27 2003-01-02 Phan Brigitte C. Dual bead assays including optical biodiscs and methods relating thereto
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US20030064058A1 (en) * 2001-09-07 2003-04-03 Nadir Askenasy Methods of utilizing bone marrow stem cells for inducing immunological tolerance
US20030086914A1 (en) * 1999-06-25 2003-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and device for inducing biological processes by micro-organs
US20030104491A1 (en) * 2000-04-30 2003-06-05 Cabantchik Ioav Zvi Molecules and methods using same for measuring non-transferrin bound iron
WO2003046201A2 (en) 2001-11-21 2003-06-05 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030124116A1 (en) * 1997-08-21 2003-07-03 Quark Biotech, Inc. Hypoxia-regulated genes
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
US20030211490A1 (en) * 2000-01-24 2003-11-13 Hanan Stein Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
WO2004018698A2 (en) 2002-08-20 2004-03-04 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US20040052769A1 (en) * 2000-11-30 2004-03-18 Yair Reisner Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20040076976A1 (en) * 2000-11-02 2004-04-22 Pan Shen Quan Aopb gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
US20040121442A1 (en) * 2002-05-05 2004-06-24 Ilan Chet Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
WO2004060135A2 (en) 2003-01-02 2004-07-22 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20040197334A1 (en) * 2003-04-02 2004-10-07 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040248093A1 (en) * 2000-11-27 2004-12-09 Coombs James Howard Magneto-optical bio-discs and systems including related methods
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
US20050008624A1 (en) * 2002-01-24 2005-01-13 Tony Peled Expansion of renewable stem cell populations
US20050022269A1 (en) * 2001-07-19 2005-01-27 Joseph Hirschberg Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US20050020499A1 (en) * 2003-05-27 2005-01-27 Bar Ilan University Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20050031618A1 (en) * 2001-01-31 2005-02-10 Dror Mevorach Induction of tolerance by apoptotic and/or necrotic cells
US20050032126A1 (en) * 2003-03-03 2005-02-10 Coombs James H. Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US6867005B2 (en) 2001-10-24 2005-03-15 Beckman Coulter, Inc. Method and apparatus for increasing the dynamic range and accuracy of binding assays
US20050069923A1 (en) * 1996-07-08 2005-03-31 Mullis Kary Banks Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
WO2005033145A1 (en) 2003-10-07 2005-04-14 Yeda Research And Development Co. Ltd. Antibodies to nik, their preparation and use
WO2005033142A2 (en) 2003-10-07 2005-04-14 Yeda Research And Development Co. Ltd. Anti-nik antibodies and uses thereof
US20050085432A1 (en) * 2001-12-26 2005-04-21 Aviva Lapidot Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20050113327A1 (en) * 1999-08-30 2005-05-26 Levava Roiz Methods of and compositions for inhibiting the proliferation of mammalian cells
WO2005051423A2 (en) 2003-11-30 2005-06-09 Yeda Research And Development Co. Ltd Methods and agents for immune modulation and methods for identifying immune modulators
US20050152912A1 (en) * 2003-03-26 2005-07-14 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050158809A1 (en) * 2002-04-16 2005-07-21 The Regents Of The University Of Califorina Methods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
US20050158822A1 (en) * 2004-01-20 2005-07-21 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20050176137A1 (en) * 1999-02-04 2005-08-11 Technion Research & Development Foundation Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050191285A1 (en) * 1993-03-17 2005-09-01 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050202098A1 (en) * 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
US20050214827A1 (en) * 1996-07-08 2005-09-29 Burstein Technologies, Inc. Assay device and method
US20050220774A1 (en) * 2002-03-18 2005-10-06 Tony Peled Methods of inducing differentiation in ex vivo expanded stem cells
US20050255101A1 (en) * 2002-02-13 2005-11-17 Technion Research And Development Foundation Ltd. Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050271643A1 (en) * 2003-08-14 2005-12-08 Iryna Sorokulova Bacterial strains, compositions including same and probiotic use thereof
US20060008479A1 (en) * 1996-04-01 2006-01-12 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20060019340A1 (en) * 1999-06-08 2006-01-26 David Naor CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US20060035980A1 (en) * 2003-04-18 2006-02-16 Scanlan Thomas S Thyronamine derivatives and analogs and methods of use thereof
US20060039897A1 (en) * 2002-03-26 2006-02-23 Tamar Lotan Stinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060051426A1 (en) * 2001-12-05 2006-03-09 Gershon Golomb Nanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US20060079941A1 (en) * 2004-10-12 2006-04-13 Eli Ovsyshcher Methods and implantable devices for treating supraventricular arrhythmias
US7033747B2 (en) 2001-04-11 2006-04-25 Nagaoka & Co., Ltd Multi-parameter assays including analysis discs and methods relating thereto
US20060095241A1 (en) * 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060099273A1 (en) * 2000-09-28 2006-05-11 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20060123516A1 (en) * 2003-05-22 2006-06-08 Gil Ronen Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
US20060134680A1 (en) * 2004-12-22 2006-06-22 Alexander Kotlyar Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20060148078A1 (en) * 2002-11-29 2006-07-06 Sharon Gerecht-Nir Method of dynamically culturing embryonic stem cells
US20060159769A1 (en) * 2000-09-28 2006-07-20 Nanocyte Inc. Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1683874A2 (en) 2000-08-29 2006-07-26 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US7087395B1 (en) 2001-01-16 2006-08-08 Quest Diagnostics Investments Incorporated Vitamin D assay
WO2006090388A2 (en) 2005-02-25 2006-08-31 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Fruit cell culture extract for treating inflammation
US7101839B1 (en) 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US20060211064A1 (en) * 2005-03-18 2006-09-21 Hyesook Kim Detection of hypertension using glucuronidated metabolic products
US20060234947A1 (en) * 2002-01-31 2006-10-19 Tel Aviv University Future Technology Development L.P Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060234203A1 (en) * 2005-04-19 2006-10-19 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060260002A1 (en) * 2003-06-19 2006-11-16 Gil Ronen Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20060257429A1 (en) * 2003-10-23 2006-11-16 Dreier Kimberly J Vaccine for periodontal disease
US20060257865A1 (en) * 2001-10-23 2006-11-16 Simon Mallal Method for identification and development of therapeutic agents
US20060278093A1 (en) * 2004-01-13 2006-12-14 Eytan Biderman Feeding formula appliance
WO2006134602A2 (en) 2005-06-16 2006-12-21 Ramot At Tel Aviv University Ltd. Isolated cells and populations comprising same for the treatment of cns diseases
US20060292559A1 (en) * 2005-06-23 2006-12-28 Beckman Coulter, Inc. Cell-based microarrays, and methods for their preparation and use
US20070032421A1 (en) * 2003-12-12 2007-02-08 Efrat Levy Methods and compositions relating to cystatin C
WO2007020638A2 (en) 2005-08-15 2007-02-22 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A2 (en) 2005-08-24 2007-03-01 Yeda Research And Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007031996A1 (en) 2005-09-12 2007-03-22 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
WO2007034487A1 (en) 2005-09-22 2007-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20070077652A1 (en) * 2004-09-16 2007-04-05 Tony Peled Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US7223902B1 (en) 1999-11-19 2007-05-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US20070160546A1 (en) * 2000-09-28 2007-07-12 Tamar Lotan Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070184530A1 (en) * 2006-02-03 2007-08-09 Fuad Fares Long-acting veterinary polypeptides and methods of producing and administering same
WO2007091254A1 (en) 2006-02-06 2007-08-16 Rappaport Family Institute For Research In The Medical Sciences Methods and kit for diagnosing t1dm
US20070196369A1 (en) * 2002-02-20 2007-08-23 Hoogenboom Henricus Renerus J MHC-peptide complex binding ligands
US7270810B2 (en) 2000-01-05 2007-09-18 Yeda Research And Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
WO2007110869A2 (en) 2006-03-28 2007-10-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to warfarin resistance
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20070281883A1 (en) * 2006-06-05 2007-12-06 Hanna Rosenfeld Development of follicle stimulating hormone agonists and antagonists in fish
US20080004234A1 (en) * 2004-07-06 2008-01-03 Segev Laboratories Limited System for delivering therapeutic agents into living cells and cells nuclei
WO2008010228A2 (en) 2006-07-20 2008-01-24 Yeda Research And Development Co. Ltd. Photosyntheticorganisms and compositions and methods of generating same
WO2008026198A2 (en) 2006-08-28 2008-03-06 Yeda Research And Development Co. Ltd. Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US7347972B1 (en) 1998-07-22 2008-03-25 Jin Po Lee Multiple analyte assay device
US20080082678A1 (en) * 2005-01-16 2008-04-03 Zlango Ltd. Communications Network System and Methods for Using Same
WO2008041183A2 (en) 2006-10-05 2008-04-10 Technion Research & Development Foundation Ltd. Microtubes and methods of producing same
US20080131419A1 (en) * 2004-09-29 2008-06-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant Human T2 Rnase and Uses Thereof
US20080138840A1 (en) * 2006-09-08 2008-06-12 Collins Michael T Assay for antibodies to mycobacterium paratuberculosis
WO2008084410A2 (en) 2007-01-04 2008-07-17 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2008093341A2 (en) 2007-01-31 2008-08-07 Technion Research & Development Foundation Ltd. Electrospun scaffolds and methods of generating and using same
WO2008093342A2 (en) 2007-02-01 2008-08-07 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
WO2008097870A2 (en) 2007-02-02 2008-08-14 Baylor Research Institute Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc- asgpr)
US20080199895A1 (en) * 2006-10-05 2008-08-21 Yeda Research And Development Co. Ltd. Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20080216022A1 (en) * 2005-01-16 2008-09-04 Zlango Ltd. Iconic Communication
US20080233140A1 (en) * 2007-02-23 2008-09-25 Baylor Research Institute Therapeutic Applications of Activation of Human Antigen-Presenting Cells Through Dectin-1
US20080241170A1 (en) * 2007-02-02 2008-10-02 Baylor Research Institute Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells
WO2008120202A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A1 (en) 2007-04-02 2008-10-09 Ramot At Tel Aviv University Ltd. Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
US20080254044A1 (en) * 2007-02-02 2008-10-16 Baylor Research Institute Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
US20080254047A1 (en) * 2007-02-23 2008-10-16 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through CLEC-6
US7442781B2 (en) 2001-08-16 2008-10-28 Urifer Ltd. Diagnosis, prevention and treatment of cancer
US20080267984A1 (en) * 2007-02-23 2008-10-30 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1)
WO2008132753A2 (en) 2007-05-01 2008-11-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for detecting fetal cells in the maternal blood
US20080279828A1 (en) * 2002-01-25 2008-11-13 Tony Peled Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20090004158A1 (en) * 1998-02-17 2009-01-01 Tony Peled Methods of controlling proliferation and differentiation of stem and progenitor cells
US20090013087A1 (en) * 2005-01-18 2009-01-08 Zlango Ltd. Communications Network System and Methods For Using Same
WO2009010968A2 (en) 2007-07-15 2009-01-22 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US20090053224A1 (en) * 2007-08-02 2009-02-26 Arresto Biosciences Lox and loxl2 inhibitors and uses thereof
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US20090068669A1 (en) * 2007-09-12 2009-03-12 Elias Georges Slc9a3r1 directed diagnostics for neoplastic disease
WO2009034574A2 (en) 2007-09-12 2009-03-19 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
EP2050826A2 (en) 2007-10-16 2009-04-22 Roche Diagnostics GmbH Reagents and methods for detecting neisseria gonorrhoeae
US20090118132A1 (en) * 2004-11-04 2009-05-07 Roche Molecular Systems, Inc. Classification of Acute Myeloid Leukemia
EP2058275A1 (en) 2003-01-07 2009-05-13 Ramot at Tel-Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US20090123553A1 (en) * 2002-12-09 2009-05-14 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US20090126042A1 (en) * 2004-06-14 2009-05-14 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090143321A1 (en) * 2005-07-07 2009-06-04 Avraham Hochberg Nucleic acid agents for downregulating h19 and methods of using same
EP2071021A2 (en) 2007-12-12 2009-06-17 University of South Florida Bone marrow-derived neuronal cells
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2009083958A2 (en) 2007-12-27 2009-07-09 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US20090209041A1 (en) * 2002-09-06 2009-08-20 Tel Aviv University Future Technology Development L.P. Peptides and methods for inhibiting amyloid formation
WO2009104174A2 (en) 2008-02-21 2009-08-27 Technion Research & Development Foundation Ltd . A method of attaching a cell-of-interest to a microtube
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US20090253170A1 (en) * 2003-06-19 2009-10-08 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
US20090293146A1 (en) * 2006-12-20 2009-11-26 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
US20090305302A1 (en) * 2008-03-18 2009-12-10 Collins Michael T Mycobacterial culture screening test for mycobacterium avium complex bacteria
EP2149585A1 (en) 2003-11-04 2010-02-03 Novartis Vaccines and Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
WO2010017544A2 (en) 2008-08-08 2010-02-11 Genisphere, Inc. Long-acting dna dendrimers and methods thereof
WO2010016806A1 (en) 2008-08-08 2010-02-11 Agency For Science, Technology And Research (A*Star) Vhz for diagnosis and treatment of cancers
US20100055033A1 (en) * 2006-04-07 2010-03-04 The Government Of The United States Of America As Represented By The Secretary Antibody compositions and methods for treatment of neoplastic disease
WO2010031006A1 (en) 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Ischemic tissue cell therapy
WO2010029545A2 (en) 2008-09-11 2010-03-18 Ben Gurion University Of The Negev Research And Development Authority Compositions and methods for treating s. pneumoniae infection
US20100068135A1 (en) * 2005-08-08 2010-03-18 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
WO2010035261A2 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US20100081177A1 (en) * 2008-09-05 2010-04-01 TransAlgae Ltd Decreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
US20100080813A1 (en) * 2008-07-25 2010-04-01 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2174668A2 (en) 2004-11-14 2010-04-14 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100092386A1 (en) * 2007-04-23 2010-04-15 David Segev System for delivering therapeutic agents into living cells and cells nuclei
US20100105759A1 (en) * 2007-01-16 2010-04-29 Abraham Hochberg H19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100105608A1 (en) * 2002-01-31 2010-04-29 Tel Aviv University Future Technology Development L.P. Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
EP2182052A1 (en) 2002-10-07 2010-05-05 Technion Research and Development Foundation, Ltd. Human foreskin cells suitable for culturing stem cells
WO2010049897A2 (en) 2008-10-30 2010-05-06 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
EP2186530A1 (en) 2000-11-17 2010-05-19 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2010055525A1 (en) 2008-11-17 2010-05-20 Technion Research & Development Foundation Ltd. Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
US20100135994A1 (en) * 2008-07-16 2010-06-03 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
WO2010061383A1 (en) 2008-11-26 2010-06-03 Biodalia Microbiological Technologies Ltd. A method of in-situ enrichment of foods with fructan
WO2010064231A1 (en) 2008-12-02 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A1 (en) 2008-12-03 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to cancer
US20100154077A1 (en) * 2007-04-09 2010-06-17 Evogene Ltd. Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
WO2010076756A2 (en) 2008-12-29 2010-07-08 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076642A1 (en) 2008-12-29 2010-07-08 Tel Hashomer Medical Research, Infrastructure And Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010076794A1 (en) 2008-12-31 2010-07-08 Technion Research & Development Foundation Ltd. Method of denitrifying brine and systems capable of same
WO2010076788A2 (en) 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010086867A2 (en) 2009-02-02 2010-08-05 Ramot At Tel Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010086856A2 (en) 2009-02-01 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
EP2216033A2 (en) 2003-03-06 2010-08-11 Yeda Research and Development Co. Ltd. Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
WO2010089707A1 (en) 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
US20100209415A1 (en) * 2009-01-06 2010-08-19 Victoria Smith Chemotherapeutic methods and compositions
WO2010097793A2 (en) 2009-02-26 2010-09-02 Tel Hashomer Medical Research Infrastructure And Services Ltd. Isolated populations of renal stem cells and methods of isolating and using same
US20100221233A1 (en) * 2003-12-15 2010-09-02 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
WO2010100595A2 (en) 2009-03-02 2010-09-10 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A1 (en) 2009-04-01 2010-10-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
EP2243492A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2243491A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
WO2010135663A2 (en) 2009-05-21 2010-11-25 The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2010137017A2 (en) 2009-05-27 2010-12-02 Yeda Research And Development Co. Ltd. Proteasome inhibitors and uses thereof
WO2010137021A2 (en) 2009-05-27 2010-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue
WO2010137020A1 (en) 2009-05-28 2010-12-02 Yeda Research And Development Co. Ltd. Methods of treating inflammation
WO2010137013A1 (en) 2009-05-27 2010-12-02 Ramot At Tel Aviv University Ltd. Crystallized photosystem i units from the pea plant and their use in solid state devices
US20100319088A1 (en) * 2007-07-24 2010-12-16 Gil Ronen Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
WO2010150259A1 (en) 2009-06-24 2010-12-29 Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical Center Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2011004361A2 (en) 2009-07-09 2011-01-13 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
US20110020357A1 (en) * 2008-04-09 2011-01-27 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
WO2011010309A1 (en) 2009-07-21 2011-01-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. A method of diagnosing cancer
EP2279726A2 (en) 2005-05-26 2011-02-02 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2011013130A2 (en) 2009-07-31 2011-02-03 Ramot At Tel-Aviv University Ltd. Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US20110033473A1 (en) * 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
US7888003B2 (en) 2004-09-08 2011-02-15 The United States Of America As Represented By The Department Of Health And Human Services Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
WO2011021171A1 (en) 2009-08-21 2011-02-24 Beeologics, Llc Preventing and curing beneficial insect diseases via plant transcribed molecules
US20110044981A1 (en) * 2009-08-21 2011-02-24 Spangler Rhyannon Methods and compositions for treatment of pulmonary fibrotic disorders
WO2011021194A2 (en) 2009-08-17 2011-02-24 Technion Research & Development Foundation Ltd. Pericyte progenitor cells and methods of generating and using same
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
EP2289567A2 (en) 2003-12-22 2011-03-02 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2011024172A2 (en) 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
EP2292762A2 (en) 2002-12-20 2011-03-09 Board of Regents, The University of Texas System VMP-like sequences of pathogenic Borrelia species and strains
EP2295980A1 (en) 2002-10-30 2011-03-16 Yissum Research Development Company, of The Hebrew University of Jerusalem Molecules and methods using same for measuring non-transferrin bound iron
WO2011030332A2 (en) 2009-09-08 2011-03-17 Yeda Research And Development Co. Ltd. Methods for hematopoietic precursor mobilization
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
WO2011030336A1 (en) 2009-09-08 2011-03-17 Ramot At Tel-Aviv University Ltd. Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011033511A1 (en) 2009-09-17 2011-03-24 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011033506A2 (en) 2009-09-17 2011-03-24 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2301575A1 (en) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
US20110076272A1 (en) * 2009-08-21 2011-03-31 Victoria Smith Therapeutic methods and compositions
US20110076739A1 (en) * 2009-08-21 2011-03-31 Mccauley Scott Catalytic domains from lysyl oxidase and loxl2
US20110081706A1 (en) * 2009-10-02 2011-04-07 TransAlgae Ltd Method and system for efficient harvesting of microalgae and cyanobacteria
EP2308994A1 (en) 2001-03-23 2011-04-13 Yeda Research And Development Co., Ltd. Methods for determining a risk to develop cancer
EP2312315A1 (en) 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2011045796A1 (en) 2009-10-14 2011-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for controlling varroa mites in bees
WO2011046570A1 (en) 2009-10-16 2011-04-21 The University Of Medicine And Dentistry Of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
US20110091454A1 (en) * 2004-01-27 2011-04-21 Alex Diber Methods and systems for annotating biomolecular sequences
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
US20110097771A1 (en) * 2008-05-22 2011-04-28 Eyal Emmanuel Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
EP2316441A1 (en) 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
EP2316950A1 (en) 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2319857A2 (en) 2003-03-04 2011-05-11 Yeda Research And Development Co., Ltd. Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
WO2011055366A1 (en) 2009-11-08 2011-05-12 Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of Israel Mo-1 conditional knock-out non-human animal and uses thereof
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
WO2011058557A1 (en) 2009-11-12 2011-05-19 Ramot At Tel-Aviv University Ltd. Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011063198A2 (en) 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
WO2011064773A1 (en) 2009-11-24 2011-06-03 Collplant Ltd. Method of generating collagen fibers
WO2011064669A2 (en) 2009-11-30 2011-06-03 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
EP2330132A1 (en) 2003-04-04 2011-06-08 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2011067745A2 (en) 2009-12-06 2011-06-09 Rosetta Green Ltd. Compositions and methods for enhancing plants resistance to abiotic stress
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US20110145946A1 (en) * 2008-08-18 2011-06-16 Evogene Ltd. Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
US20110147993A1 (en) * 2008-04-10 2011-06-23 Objet Geometries Ltd. System and method for three dimensional model printing
US20110150874A1 (en) * 2006-05-19 2011-06-23 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
EP2338896A2 (en) 2002-12-12 2011-06-29 R.B.T. (Rakuto Bio Technologies) Ltd. Use of lignin peroxidase in skin and hair lightening
WO2011080674A2 (en) 2009-12-28 2011-07-07 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080740A1 (en) 2009-12-29 2011-07-07 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
WO2011086509A1 (en) 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
US20110177112A1 (en) * 2007-11-02 2011-07-21 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papilloma virus infection
WO2011092700A1 (en) 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
WO2011099006A2 (en) 2010-02-11 2011-08-18 Yeda Research And Development Co. Ltd. Enzymatic systems for carbon fixation and methods of generating same
EP2359854A1 (en) 2000-08-08 2011-08-24 Technion Research and Development Foundation, Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
WO2011104708A2 (en) 2010-02-24 2011-09-01 Ben Gurion University Of The Negev Research And Development Authority Methods for inhibiting necrosis
WO2011107994A1 (en) 2010-03-04 2011-09-09 Yeda Research And Development Co. Ltd. Methods of measuring protein stability
WO2011107939A1 (en) 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
EP2365087A2 (en) 2003-05-22 2011-09-14 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2011111034A1 (en) 2010-03-08 2011-09-15 Yeda Research And Development Co. Ltd. Recombinant protein production in heterologous systems
WO2011111050A2 (en) 2010-03-11 2011-09-15 Jacob Edrei Methods of generating hydrogen
EP2366775A1 (en) 2006-03-23 2011-09-21 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110229495A1 (en) * 2003-07-07 2011-09-22 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
EP2368569A2 (en) 2006-01-18 2011-09-28 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A1 (en) 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011135527A2 (en) 2010-04-28 2011-11-03 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2011138785A2 (en) 2010-05-05 2011-11-10 Rappaport Family Institute For Research In The Medical Sciences Use of ccl1 in therapy
WO2011138778A2 (en) 2010-05-04 2011-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of identifying inhibitors of polypeptides-of-interest
WO2011138776A2 (en) 2010-05-06 2011-11-10 Hervana Ltd. Biologic female contraceptives
WO2011141914A1 (en) 2010-05-13 2011-11-17 Tel Hashomer Medical Research Infrastructure And Services Ltd. Isolated populations of adult renal cells and methods of isolating and using same
EP2390312A1 (en) 2005-11-29 2011-11-30 Gamida Cell Ltd. Methods of improving stem cell homing and engraftment
WO2011151833A1 (en) 2010-06-03 2011-12-08 Ramot At Tel-Aviv University Ltd. Methods of treating diabetes and compositions capable of same
WO2011154940A1 (en) 2010-06-07 2011-12-15 Osnat Ashur-Fabian Methods and kits for diagnosing conditions related to hypoxia
WO2011158242A2 (en) 2010-06-16 2011-12-22 Futuragene Israel Ltd. Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A2 (en) 2010-06-16 2011-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of diagnosing and treating cancer
US8088160B2 (en) 2000-07-20 2012-01-03 Multi-Gene Vascular Systems Ltd. (“MGVS”) Drug-eluting intravascular prostheses and methods of use
WO2012003474A2 (en) 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants
WO2012007919A2 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007951A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012007950A2 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
WO2012014207A2 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A2 (en) 2010-07-27 2012-02-02 Yeda Research And Development Co. Ltd. Methods and systems for assessing clonality of cell cultures
WO2012014205A1 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
WO2012025914A1 (en) 2010-08-22 2012-03-01 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
EP2425841A1 (en) 2000-11-24 2012-03-07 Vascular Biogenics Ltd. Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
WO2012032510A1 (en) 2010-09-07 2012-03-15 Yeda Research And Development Co. Ltd. Primers for amplifying dna and methods of selecting same
WO2012032520A1 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032521A2 (en) 2010-09-07 2012-03-15 Technion Research & Development Foundation Ltd. Novel methods and culture media for culturing pluripotent stem cells
WO2012032525A2 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. An immunosuppressive drug combination for a stable and long term engraftment
WO2012032519A2 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing parkinson's disease
WO2012034067A1 (en) 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012032526A2 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012035539A1 (en) 2010-09-15 2012-03-22 Ramot At Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
WO2012038956A1 (en) 2010-09-20 2012-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
EP2441840A1 (en) 2005-07-18 2012-04-18 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
WO2012052872A2 (en) 2010-10-17 2012-04-26 Yeda Research And Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012056452A2 (en) 2010-10-27 2012-05-03 Nanocyte (Israel) Ltd. Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1 (en) 2010-10-28 2012-05-03 Yeda Research And Development Co. Ltd. Methods of generating antibodies to metalloenzymes
WO2012059925A2 (en) 2010-11-04 2012-05-10 Ben-Gurion University Of The Negev Research And Development Authority Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012059922A2 (en) 2010-11-03 2012-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Transgenic plants with improved saccharification yields and methods of generating same
WO2012066495A2 (en) 2010-11-17 2012-05-24 Ben Gurion University Of The Negev Research And Development Authority T-cell therapy to neurodegenerative diseases
EP2457999A2 (en) 2002-12-16 2012-05-30 Technion Research & Development Foundation Ltd. Culture medium for pluropotent stem cells
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
EP2463382A1 (en) 2010-12-07 2012-06-13 Enterologics, Inc. Method for identifying E. Coli M-17
WO2012081029A1 (en) 2010-12-15 2012-06-21 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
WO2012090205A2 (en) 2010-12-28 2012-07-05 Kamedis Ltd. Plant extracts for the treatment and prevention of infections
WO2012098537A1 (en) 2011-01-20 2012-07-26 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012104851A1 (en) 2011-01-31 2012-08-09 Yeda Research And Development Co. Ltd. Methods of diagnosing disease using overlap extension pcr
EP2487182A2 (en) 2005-07-07 2012-08-15 FULCRUM SP Ltd. SP1 polypeptides, modified SP1 polypeptides and uses thereof
US8252588B2 (en) 2003-04-08 2012-08-28 Yeda Research And Development Co. Ltd. Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
WO2012114339A1 (en) 2011-02-23 2012-08-30 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A1 (en) 2011-03-03 2012-09-07 Ramot At Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
WO2012117406A2 (en) 2011-03-02 2012-09-07 Futuragene Israel Ltd. Bacterial resistant transgenic plants
WO2012120518A1 (en) 2011-03-08 2012-09-13 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
EP2500428A2 (en) 2007-07-11 2012-09-19 Yeda Research and Development Co. Ltd. Nucleic acid construct systems capable of diagnosing or treating a cell state
WO2012123949A1 (en) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012123938A1 (en) 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
WO2012127475A1 (en) 2011-03-24 2012-09-27 Neurim Pharmaceuticals (1991) Ltd. Neuroprotective peptides
WO2012127320A1 (en) 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
EP2508596A2 (en) 2002-02-21 2012-10-10 Bayer Healthcare MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
WO2012137202A1 (en) 2011-04-05 2012-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012140519A2 (en) 2011-04-15 2012-10-18 Pluristem Ltd. Methods and systems for harvesting cells
WO2012150600A2 (en) 2011-05-04 2012-11-08 Ramot At Tel-Aviv University Ltd. Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en) 2011-05-12 2012-11-15 Rakuto Bio Technologies Ltd. Methods and device for lightening skin complexion
WO2012156976A1 (en) 2011-05-16 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of producing artemisinin in non-host plants and vectors for use in same
EP2526953A1 (en) 2003-07-15 2012-11-28 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP2527441A2 (en) 2007-07-15 2012-11-28 Technion Research & Development Foundation Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
WO2012160526A2 (en) 2011-05-23 2012-11-29 Ofir Menashe Formulations of microorganism comprising particles and uses of same
US8323636B2 (en) 2006-02-03 2012-12-04 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2529754A1 (en) 2007-05-03 2012-12-05 Agency For Science, Technology And Research (A*star) Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
WO2012164380A2 (en) 2011-05-31 2012-12-06 Hutchison Biofilm Medical Solutions Limited Dispersion and detachment of cell aggregates
WO2012172555A1 (en) 2011-06-14 2012-12-20 Yeda Research And Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A1 (en) 2011-06-23 2012-12-27 Kaiima Bio Agritech Ltd. Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
WO2013011347A1 (en) 2011-07-18 2013-01-24 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2013011507A1 (en) 2011-07-20 2013-01-24 Kaiima Bio Agritech Ltd. Maize plants having a partially or fully multiplied genome and uses thereof
EP2550982A1 (en) 2011-07-27 2013-01-30 Technion Research & Development Foundation Ltd. Devices for surgical applications
WO2013018060A2 (en) 2011-08-04 2013-02-07 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013024481A1 (en) 2011-08-14 2013-02-21 Kaiima Bio Agritech Ltd. Durum wheat plants having a partially or fully multiplied genome and uses thereof
EP2561889A2 (en) 2002-08-01 2013-02-27 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US8388954B2 (en) 2003-04-09 2013-03-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
WO2013035099A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013035071A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Novel risk biomarkers for lung cancer
US8415318B2 (en) 2001-10-19 2013-04-09 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
EP2581445A1 (en) 2007-08-15 2013-04-17 Yeda Research And Development Co. Ltd. Regulators of MMP-9 and uses thereof
WO2013054331A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US8426166B2 (en) 2006-02-03 2013-04-23 Prolor Biotech Inc. Long-acting polypeptides and methods of producing same
WO2013056377A1 (en) 2011-10-21 2013-04-25 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en) 2011-10-27 2013-05-02 Yeda Research And Development Co. Ltd. Method of treating cancer
WO2013067076A2 (en) 2011-11-03 2013-05-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
EP2591789A2 (en) 2007-09-19 2013-05-15 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2013076729A1 (en) 2011-11-23 2013-05-30 Danziger Dan Flower Farm Otomeria plants
WO2013076730A1 (en) 2011-11-27 2013-05-30 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis and compositions capable of same
EP2599790A1 (en) 2007-11-26 2013-06-05 Yissum Research Development Company of The Hebrew University of Jerusalem Compositions comprising fibrous polypeptides and polysachharides
WO2013084190A1 (en) 2011-12-08 2013-06-13 Yeda Research And Development Co. Ltd. Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A1 (en) 2011-12-20 2013-06-27 Collplant Ltd. Collagen coated synthetic polymer fibers
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
WO2013098813A1 (en) 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013098820A1 (en) 2011-12-28 2013-07-04 Kaiima Bio Agritech Ltd. Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
EP2620493A1 (en) 2008-05-28 2013-07-31 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
WO2013121416A1 (en) 2012-02-14 2013-08-22 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
WO2013121427A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013121405A1 (en) 2012-02-19 2013-08-22 Protalix Ltd. Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013124817A2 (en) 2012-02-22 2013-08-29 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013124816A2 (en) 2012-02-22 2013-08-29 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons
EP2633854A1 (en) 2008-12-05 2013-09-04 Yeda Research And Development Co. Ltd. miRNA-9 or miRNA-9* for use in treating MND
WO2013128454A1 (en) 2012-03-01 2013-09-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Male sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013132495A1 (en) 2012-03-07 2013-09-12 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1 (en) 2012-03-15 2013-09-19 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
WO2013140247A1 (en) 2012-03-20 2013-09-26 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013140389A1 (en) 2012-03-22 2013-09-26 Ramot At Tel-Aviv University Ltd. Plif multimeric peptides and uses thereof
WO2013153553A2 (en) 2012-04-13 2013-10-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for controlling varroa mites in bees
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2013168164A1 (en) 2012-05-09 2013-11-14 Yeda Research And Development Co. Ltd. Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013183052A1 (en) 2012-06-04 2013-12-12 Prolor Biotech Inc. Pegylated oxm variants
WO2013183048A1 (en) 2012-06-03 2013-12-12 Ben-Gurion University Of The Negev Research And Development Authority Functionalized titanium binding peptides and implants coated with same
WO2014006621A1 (en) 2012-07-03 2014-01-09 Nanospun Technologies Ltd. Methods and devices for adsorption and biodegradation of petroleum
WO2014020599A1 (en) 2012-07-29 2014-02-06 Yeda Research And Development Co. Ltd. Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A1 (en) 2012-07-31 2014-02-06 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
WO2014024183A1 (en) 2012-08-06 2014-02-13 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
WO2014033723A1 (en) 2012-09-03 2014-03-06 A.B. Seeds Ltd. Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A1 (en) 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2014052588A1 (en) 2012-09-27 2014-04-03 Research Development Foundation Attenuated chikungunya virus
EP2716654A1 (en) 2005-10-24 2014-04-09 Evogene Ltd. Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
WO2014057490A1 (en) 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014064682A1 (en) 2012-10-24 2014-05-01 Yeda Research And Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A1 (en) 2012-10-29 2014-05-08 Yeda Research And Development Co. Ltd. Aptamers, multimeric aptamers and uses thereof
WO2014083567A2 (en) 2012-11-29 2014-06-05 Yeda Research And Development Co. Ltd. Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8775526B2 (en) 2006-01-16 2014-07-08 Zlango Ltd. Iconic communication
WO2014106838A2 (en) 2013-01-01 2014-07-10 A.B. Seeds Ltd. Methods of introducing dsrna to plant seeds for modulating gene expression
WO2014108850A2 (en) 2013-01-09 2014-07-17 Yeda Research And Development Co. Ltd. High throughput transcriptome analysis
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014111936A1 (en) 2013-01-17 2014-07-24 Novellusdx Ltd. Methods and systems for identifying patient specific driver mutations
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
WO2014136113A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136117A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
EP2781223A1 (en) 2007-10-19 2014-09-24 Rappaport Family Institute for Research in the Medical Sciences Compositions comprising semaphorins for the treatment of angiogenesis related diseases
WO2014147622A1 (en) 2013-03-21 2014-09-25 Collplant Ltd. Compositions comprising collagen and prp for tissue regeneration
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
WO2014155376A1 (en) 2013-03-24 2014-10-02 Biokine Therapeutics Ltd. Methods of treating myeloid leukemia
EP2789626A2 (en) 2008-09-24 2014-10-15 Tel Hashomer Medical Research Infrastructure and Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
US8865158B2 (en) 2012-05-22 2014-10-21 Ramot At Tel-Aviv University Ltd. Bacteriophages for reducing toxicity of bacteria
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2014174470A1 (en) 2013-04-23 2014-10-30 Yeda Research And Development Co. Ltd. Isolated naive pluripotent stem cells and methods of generating same
WO2014174520A1 (en) 2013-04-25 2014-10-30 Yeda Research And Development Co. Ltd. Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014174511A1 (en) 2013-04-21 2014-10-30 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014188423A1 (en) 2013-05-21 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
WO2014191995A2 (en) 2013-05-27 2014-12-04 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
EP2816117A2 (en) 2004-09-29 2014-12-24 Collplant Ltd. Collagen producing plants and methods of generating and using same
WO2014207744A1 (en) 2013-06-24 2014-12-31 Ramot At Tel-Aviv University Ltd. Omentum based scaffold and delivery system
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015015489A1 (en) 2013-07-30 2015-02-05 Biolinerx Ltd. Antibody for treating diabetes and autoimmune diseases
EP2839839A1 (en) 2007-02-28 2015-02-25 Yeda Research And Development Company Limited Nuclear targeting sequences
WO2015033337A1 (en) 2013-09-03 2015-03-12 Technion Research & Development Foundation Limited. A flap for de-novo tissue regeneration
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en) 2013-09-16 2015-03-19 Plexicure Ltd. Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A1 (en) 2013-10-31 2015-05-07 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
WO2015079413A2 (en) 2013-11-28 2015-06-04 Yeda Research And Development Co. Ltd. Synaptojanin-2 inhibitors and uses thereof
US9057092B2 (en) 2006-03-06 2015-06-16 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
EP2889041A1 (en) 2005-07-26 2015-07-01 Rutgers, The State University of New Jersey Kit of reagents for tuberculosis assay
US9096645B2 (en) 2010-11-15 2015-08-04 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9096865B2 (en) 2009-06-10 2015-08-04 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A2 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
WO2015118538A1 (en) 2014-02-06 2015-08-13 Yeda Research And Development Co. Ltd. Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015118547A1 (en) 2014-02-10 2015-08-13 Protalix Ltd. Method of maintaining disease stability in a subject having gaucher's disease
WO2015118537A2 (en) 2014-02-05 2015-08-13 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015121859A1 (en) 2014-02-11 2015-08-20 Brainstorm Cell Therapeutics Ltd. Method of qualifying cells
US9121022B2 (en) 2010-03-08 2015-09-01 Monsanto Technology Llc Method for controlling herbicide-resistant plants
WO2015132784A1 (en) 2014-03-03 2015-09-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and device for detection of pseudomonas aeruginosa
EP2923709A1 (en) 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
WO2015159293A2 (en) 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2015159295A1 (en) 2014-04-17 2015-10-22 Yeda Research And Development Co. Ltd. Methods and kits for analyzing dna binding moieties attached to dna
EP2936976A1 (en) 2008-04-21 2015-10-28 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2015166492A2 (en) 2014-04-28 2015-11-05 Yeda Research And Development Co. Ltd. Microbiome response to agents
US9182403B2 (en) 2009-05-19 2015-11-10 Zetiq Technologies Ltd. Kits for and methods of differential staining of cervical cancer cells and/or tissues
WO2015170325A2 (en) 2014-05-04 2015-11-12 Forrest Innovations Ltd. Compositions and methods for reducing pathogen-induced citrus greening
WO2015177800A2 (en) 2014-05-22 2015-11-26 Yeda Research And Development Co. Ltd. Recombinant microorganisms capable of carbon fixation
WO2015186129A1 (en) 2014-06-02 2015-12-10 Technion Research & Development Foundation Limited. Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2015198334A2 (en) 2014-06-25 2015-12-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Identification of cancer stem cells and use of same for diagnosis and treatment
EP2960250A1 (en) 2008-07-16 2015-12-30 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
WO2016009436A1 (en) 2014-07-15 2016-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
EP2990421A1 (en) 2009-04-30 2016-03-02 Tel HaShomer Medical Research Infrastructure and Services Ltd. Anti ceacam1 antibodies and methods of using same
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
US9290564B2 (en) 2012-05-24 2016-03-22 Mountgate Group Limited Compositions and methods related to the prevention and treatment of rabies infection
WO2016042561A2 (en) 2014-09-21 2016-03-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Downregulating mir-132 for the treatment of lipid related disorders
EP3006039A1 (en) 2004-03-02 2016-04-13 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
EP3009449A1 (en) 2008-07-16 2016-04-20 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP3020410A1 (en) 2008-04-18 2016-05-18 Collplant Ltd. Methods of generating and using procollagen
DE102015220401A1 (en) 2014-10-20 2016-05-19 Gen-Probe Incorporated Erythrocyte lysis solution
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
WO2016079731A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Method of analyzing microbiome
WO2016079739A2 (en) 2014-11-20 2016-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
WO2016079736A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
EP3026057A2 (en) 2009-03-09 2016-06-01 Ramot at Tel Aviv University Ltd. Compositions for prevention and treatment of neurodegenerative diseases
WO2016092555A2 (en) 2014-12-11 2016-06-16 Yeda Research And Development Co. Ltd. Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
WO2016108239A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
WO2016108244A1 (en) 2015-01-04 2016-07-07 Protalix Ltd. Modified dnase and uses thereof
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
WO2016116935A1 (en) 2015-01-21 2016-07-28 Yeda Research And Development Co. Ltd. Use of rasa2 as a prognostic and therapeutic marker for melanoma
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
US9422557B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US9422558B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
WO2016135732A1 (en) 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth
WO2016142948A1 (en) 2015-03-11 2016-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Decoy oligonucleotides for the treatment of diseases
WO2016147194A1 (en) 2015-03-19 2016-09-22 Yeda Research And Development Co. Ltd. Anti amphiregulin antibodies, compositions comprising same and uses thereof
US9458438B2 (en) 2010-04-12 2016-10-04 Ben Gurion University Of The Negev Research And Development Authority Sulfotransferase of a red microalga and uses thereof
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2016157190A1 (en) 2015-03-31 2016-10-06 Yeda Research And Development Co. Ltd. Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
WO2016162870A1 (en) 2015-04-07 2016-10-13 Ilana Nathan Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
WO2016174674A1 (en) 2015-04-27 2016-11-03 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
WO2016181393A1 (en) 2015-05-11 2016-11-17 Yeda Research And Development Co. Ltd. Citrin inhibitors for the treatment of cancer
WO2016185469A1 (en) 2015-05-21 2016-11-24 Yeda Research And Development Co. Ltd. Bacterial populations for promoting health
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
WO2016199140A1 (en) 2015-06-08 2016-12-15 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
WO2016203476A1 (en) 2015-06-18 2016-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for diagnosing and treating urothelial cancer
WO2016203477A1 (en) 2015-06-18 2016-12-22 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
US9540642B2 (en) 2013-11-04 2017-01-10 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods for controlling arthropod parasite and pest infestations
EP3115451A1 (en) 2008-09-02 2017-01-11 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
WO2017009852A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Use of anti third party central memory t cells
US9551006B2 (en) 2010-12-22 2017-01-24 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
WO2017013661A1 (en) 2015-07-22 2017-01-26 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2017017686A1 (en) 2015-07-29 2017-02-02 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
WO2017021963A1 (en) 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
WO2017021961A1 (en) 2015-08-04 2017-02-09 Yeda Research And Development Co. Ltd. Methods of screening for riboswitches and attenuators
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
WO2017021972A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
US9567579B2 (en) 2003-05-23 2017-02-14 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2017025967A1 (en) 2015-08-13 2017-02-16 Forrest Innovations Ltd. Formulations and compositions for delivery of nucleic acids to plant cells
WO2017033188A1 (en) 2015-08-24 2017-03-02 Yeda Research And Development Co. Ltd. Algal oil and biofuel and methods of producing same
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
EP3159405A1 (en) 2010-01-05 2017-04-26 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
WO2017072772A1 (en) 2015-10-29 2017-05-04 Yeda Research And Development Co. Ltd. A method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017072757A1 (en) 2015-10-25 2017-05-04 Yeda Research And Development Co. Ltd. Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2017072773A1 (en) 2015-10-27 2017-05-04 Ilana Nathan Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2017072763A1 (en) 2015-10-26 2017-05-04 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
WO2017077539A1 (en) 2015-11-03 2017-05-11 Ariel-University Research And Development Company Ltd. Compositions for regeneration and repair of neural tissue
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
WO2017118985A1 (en) 2016-01-06 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017130205A1 (en) 2016-01-31 2017-08-03 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
US9726581B2 (en) 2011-12-22 2017-08-08 Realbio Technologies Ltd. Sequential lateral flow capillary device for analyte determination
WO2017134671A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
WO2017138007A1 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Microbiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017138008A2 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2017141253A1 (en) 2016-02-16 2017-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
WO2017158610A1 (en) 2016-03-17 2017-09-21 Yeda Research And Development Co. Ltd. Methods of isolating barrel-like proteases and identifying peptides processed thereby
US9777288B2 (en) 2013-07-19 2017-10-03 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
WO2017189746A1 (en) 2016-04-27 2017-11-02 Gen-Probe Incorporated Blood cell lysis reagent
US9808534B2 (en) 2012-11-20 2017-11-07 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP3244189A1 (en) 2008-12-30 2017-11-15 Jin Po Lee Quantitative analyte assay device and method
US9822134B2 (en) 2012-10-22 2017-11-21 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US9828417B2 (en) 2006-02-03 2017-11-28 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7600128A (en) * 1975-01-27 1976-07-29 Kabi Ab Diagnostic agents, and a method for immuno-chemical determination.
CA1078712A (en) * 1975-04-28 1980-06-03 Robert C. Bogusiaski Heterogenous specific binding assay method and means for use therein
GB1549069A (en) * 1976-12-10 1979-08-01 Erba Farmitalia Enzyme linked immunoassay
GB1575267A (en) * 1977-03-15 1980-09-17 Snam Progetti Enzyme conjugates and their use in the determination of tri-iodo thyronine and of anti-tri-iodo thyronine antibody
CA1108516A (en) * 1977-11-21 1981-09-08 Stanley E. Charm Antibiotic detection method
US4279885A (en) * 1978-05-19 1981-07-21 Becton Dickinson & Company Solid phase assay
JPS54170918U (en) * 1978-05-23 1979-12-03
US4273756A (en) * 1978-07-28 1981-06-16 Abbott Laboratories Immunoassay for class specific antibodies
US4292296A (en) * 1978-09-12 1981-09-29 Baxter Travenol Laboratories, Inc. Diagnostic method
US4446231A (en) * 1979-10-03 1984-05-01 Self Colin H Immunoassay using an amplified cyclic detection system
GB2059421A (en) * 1979-10-03 1981-04-23 Self C H Assay method and reagents therefor
JPS56143955A (en) * 1980-04-10 1981-11-10 Fujirebio Inc Method for diagnosis of initial infection of syphilis
DE3016575A1 (en) * 1980-04-30 1981-11-05 Merck Patent Gmbh Method for the immunological determination of enzymes, medium for performing the method and its verwandung
JPS57193643U (en) * 1981-06-03 1982-12-08
US4447528A (en) * 1981-08-10 1984-05-08 Corning Glass Works Detecting intrinsic factor blocking site antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1588874A (en) * 1967-09-06 1970-03-16

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3654090B1 (en) * 1968-09-24 1982-07-20

Cited By (926)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4203802A (en) * 1971-05-14 1980-05-20 Syva Company Inhibitable enzyme amplification assay
US3875011A (en) * 1972-11-06 1975-04-01 Syva Co Enzyme immunoassays with glucose-6-phosphate dehydrogenase
US3904367A (en) * 1973-08-15 1975-09-09 Gen Electric Contrast enhancement for immunological film detection
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US3951748A (en) * 1974-11-11 1976-04-20 Medical Products, Inc. Sensitized matrix for detection of disease
US4343896A (en) * 1975-02-01 1982-08-10 Akzona Incorporated Method and test pack for the demonstration and determination of an antigen or antibody
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4642285A (en) * 1975-09-29 1987-02-10 Diamedix Corporation Sandwich EIA for antigen
DE2643829A1 (en) * 1975-09-29 1977-04-14 Cordis Corp A method for detecting the presence of hepatitis attributable antigens
FR2325934A1 (en) * 1975-09-29 1977-04-22 Cordis Corp Detection Method of the presence of an antigen associated to hepatitis
US4474878A (en) * 1975-09-29 1984-10-02 Cordis Laboratories, Inc. Sandwich EIA for antigen associated with hepatitis
US4116776A (en) * 1976-04-19 1978-09-26 International Radioimmune Systems, Inc. Diagnostic blood test and kit for detecting human chorionic gonadotropin
FR2367286A1 (en) * 1976-10-07 1978-05-05 Mochida Pharm Co Ltd New process and immunochemical assay reagents physiologically active substances
US4248965A (en) * 1976-10-07 1981-02-03 Mochida Seiyaku Kabushiki Kaisha Immunochemical process of measuring physiologically active substances
US4200508A (en) * 1977-02-09 1980-04-29 Hidematsu Hirai Method and composition for detecting antigenic substances
US4302534A (en) * 1977-03-16 1981-11-24 Israel Institute For Biological Research Chemiluminescent enzyme immunoassay
US4254223A (en) * 1978-04-18 1981-03-03 Akzona Incorporated Apparatus for colorimetric determination
US4240751A (en) * 1978-11-09 1980-12-23 Akzona Incorporated Method and apparatus for specific binding substances
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318707A (en) * 1978-11-24 1982-03-09 Syva Company Macromolecular fluorescent quencher particle in specific receptor assays
US4374925A (en) * 1978-11-24 1983-02-22 Syva Company Macromolecular environment control in specific receptor assays
US4337063A (en) * 1979-03-01 1982-06-29 Fuji Photo Film Co., Ltd. Competitive immunoassay using spectral sensitizer label
US4331444A (en) * 1979-03-01 1982-05-25 Fuji Photo Film Co., Ltd. Competitive immunoassay using silver halide fogging agent
US4269938A (en) * 1979-03-08 1981-05-26 Eastman Kodak Company Assay of peroxidatively active materials
WO1980002747A1 (en) * 1979-05-31 1980-12-11 Rapidex Ltd Ultrasensitive enzymatic radioimmunoassay method
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
WO1981002792A1 (en) * 1980-03-20 1981-10-01 Res Triangle Inst Detection of antibiotics in milk
US4362531A (en) * 1980-04-15 1982-12-07 Technicon Instruments Corporation Agglutination immunoassays carried out with agent to reduce non-specific interferences
US6406920B1 (en) 1980-06-20 2002-06-18 Inverness Medical Switzerland Gmbh Processes and apparatus for carrying out specific binding assays
US5610077A (en) * 1980-06-20 1997-03-11 Unilever Patent Holdings B.V. Processes and apparatus for carrying out specific binding assays
US6391563B1 (en) 1980-07-28 2002-05-21 Akzo Nobel N.V. Method for the determination of antigens with the aid of three or more monoclonal antibodies
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4323647A (en) * 1980-10-15 1982-04-06 University Of Miami Steric hindrance enzyme immunoassay
WO1982002601A1 (en) * 1981-01-23 1982-08-05 Hospital Supply Corp American Solid phase system for ligand assay
US4517288A (en) * 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
EP0060700A1 (en) * 1981-03-13 1982-09-22 Immuno-Mycologics, Inc. Assay method and device
US4446238A (en) * 1981-03-19 1984-05-01 Janssen Pharmaceutica N.V. Bright field light microscopic method of localizing tissue antigens
US4592995A (en) * 1981-03-30 1986-06-03 Dainippon Pharmaceutical Co., Ltd. Reagent for streptococcal anti-esterase assay
US4604365A (en) * 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
WO1983000877A1 (en) * 1981-08-31 1983-03-17 Icl Scient Glucose oxidase immunohistochemical detection of antinuclear antibodies
US4452886A (en) * 1981-09-21 1984-06-05 Henry Robert P Novel photon absorbing or emitting polymers and their use as reagents in immunoassay systems
US4446232A (en) * 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US4753875A (en) * 1981-11-02 1988-06-28 Ryan James W Method for assaying proteases with tagged proteinaceous inhibitors
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
US4469787A (en) * 1982-05-14 1984-09-04 Mallinckrodt Inc. Immunoassay involving soluble complex of second antibody and labeled binding protein
US4503143A (en) * 1982-08-20 1985-03-05 Btc Diagnostics Limited Partnership Enzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
WO1986004421A1 (en) * 1982-08-20 1986-07-31 Hygeia Sciences Limited Partnership Enzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
US4530900A (en) * 1982-09-13 1985-07-23 Seragen Diagnostics Inc. Soluble insoluble polymers in enzymeimmunoassay
US5047330A (en) * 1983-08-17 1991-09-10 Commissariat A L'energie Atomique Compound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
WO1985002260A1 (en) * 1983-11-08 1985-05-23 Quidel Rapid plunger immunoassay method and apparatus
WO1985003950A1 (en) * 1984-03-08 1985-09-12 Scripps Clinic And Research Foundation A sv40 expression vector containing hbxag as an expression marker
US5534405A (en) * 1984-03-08 1996-07-09 The Scripps Research Institute Antibodies, diagnostic systems and methods for assaying HBxAg
WO1985004397A1 (en) 1984-03-23 1985-10-10 Oncogen Platelet related growth regulator
US4665020A (en) * 1984-05-30 1987-05-12 United States Department Of Energy Flow cytometer measurement of binding assays
US4812395A (en) * 1984-11-05 1989-03-14 E. I. Du Pont De Nemours And Company Method for detecting enzymatic activity using particle agglutination
US4812396A (en) * 1984-11-05 1989-03-14 E. I. Du Pont De Nemours And Company Method for detecting enzymatic activity using particle agglutination
US4713347A (en) * 1985-01-14 1987-12-15 Sensor Diagnostics, Inc. Measurement of ligand/anti-ligand interactions using bulk conductance
US4824784A (en) * 1985-04-08 1989-04-25 Hygeia Sciences, Incorporated Chromogenic solution for immunoassay
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US4868108A (en) * 1985-12-12 1989-09-19 Hygeia Sciences, Incorporated Multiple-antibody detection of antigen
US4808522A (en) * 1986-04-24 1989-02-28 Moskovsky Gosudarstvennx Universitet Imeni M. V. Lomonoso VA Enzyme immunoassays using inorganic pyrophosphatase
US5334513A (en) * 1988-05-17 1994-08-02 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US5451507A (en) * 1988-05-17 1995-09-19 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US5468647A (en) * 1988-05-17 1995-11-21 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US5624809A (en) * 1988-05-17 1997-04-29 Behringwerke Ag Device for immunochromatographic analysis
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5328828A (en) * 1988-12-23 1994-07-12 Syntex (U.S.A.) Inc. Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5726015A (en) * 1991-05-15 1998-03-10 Vanderbilt University Method to determine metastatic potential of tumor cells
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050191285A1 (en) * 1993-03-17 2005-09-01 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US6664370B2 (en) 1993-03-17 2003-12-16 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US7601697B2 (en) 1993-03-17 2009-10-13 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US6075122A (en) * 1993-03-17 2000-06-13 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7247703B2 (en) 1993-03-17 2007-07-24 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5846538A (en) * 1993-03-17 1998-12-08 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US20040082758A1 (en) * 1993-03-17 2004-04-29 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US8524491B2 (en) 1993-03-17 2013-09-03 University Of Washington Through Its Center For Commercialization Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5876712A (en) * 1993-03-17 1999-03-02 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7655239B2 (en) 1993-03-17 2010-02-02 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20080076904A1 (en) * 1993-03-17 2008-03-27 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5672475A (en) * 1993-05-06 1997-09-30 Chiron Diagnostics Corporation Mixed luminescent conjugate test
US5837535A (en) * 1994-06-13 1998-11-17 Henry Ford Health System Neuronal-neonatal gene: neuronatin
US5698686A (en) * 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US6387619B1 (en) 1994-10-20 2002-05-14 Arch Development Telomerase compositions and methods
US5916752A (en) * 1994-10-20 1999-06-29 Arch Development Corporation Telomerase screening methods
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US6200749B1 (en) 1995-05-16 2001-03-13 Ramot-University Authority For Applied Research And Industrial Development Ltd. Mutated forms of the ataxia-telangiectasia gene and method to screen for a partial A-T phenotype
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5858661A (en) * 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US5807552A (en) * 1995-08-04 1998-09-15 Board Of Regents, The University Of Texas System Compositions for conferring immunogenicity to a substance and uses thereof
WO1997005886A1 (en) * 1995-08-04 1997-02-20 Board Of Regents, The University Of Texas System Compositions for conferring immunogenicity to a peptide
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US20060008479A1 (en) * 1996-04-01 2006-01-12 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6312901B2 (en) 1996-07-08 2001-11-06 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US20050214827A1 (en) * 1996-07-08 2005-09-29 Burstein Technologies, Inc. Assay device and method
US20020106661A1 (en) * 1996-07-08 2002-08-08 Burstein Laboratories, Inc. Optical disk-based assay devices and methods
US6342349B1 (en) 1996-07-08 2002-01-29 Burstein Technologies, Inc. Optical disk-based assay devices and methods
US20050069923A1 (en) * 1996-07-08 2005-03-31 Mullis Kary Banks Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US6331275B1 (en) 1996-07-08 2001-12-18 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
US6740738B2 (en) 1997-08-21 2004-05-25 Quark Biotech, Inc. Antibody against hypoxia proteins
US20030124116A1 (en) * 1997-08-21 2003-07-03 Quark Biotech, Inc. Hypoxia-regulated genes
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
US6284496B1 (en) 1997-10-03 2001-09-04 University Of South Florida DNA vector for determining the presence of out-of-reading-frame mutations
US6482389B1 (en) 1997-10-17 2002-11-19 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
US20090004158A1 (en) * 1998-02-17 2009-01-01 Tony Peled Methods of controlling proliferation and differentiation of stem and progenitor cells
US8202724B2 (en) 1998-02-17 2012-06-19 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US7855075B2 (en) 1998-02-17 2010-12-21 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US20110045589A1 (en) * 1998-02-17 2011-02-24 Gamida Cell Ltd. Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US7347972B1 (en) 1998-07-22 2008-03-25 Jin Po Lee Multiple analyte assay device
US6187563B1 (en) 1998-08-07 2001-02-13 Yale University βIV-spectrin-polypeptides and nucleic acids encoding same
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
US20050032039A1 (en) * 1998-11-17 2005-02-10 Sastry K. Jagannadha HIV-specific T-cell induction
US7306804B2 (en) 1998-11-17 2007-12-11 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
EP2311938A1 (en) 1999-02-04 2011-04-20 Pluristem Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050180958A1 (en) * 1999-02-04 2005-08-18 Technion Research & Development Foundation Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7678573B2 (en) 1999-02-04 2010-03-16 Pluristem Ltd. Method of preparing a conditioned medium from a confluent stromal cell culture
US20050181504A1 (en) * 1999-02-04 2005-08-18 Technion Research & Development Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7534609B2 (en) 1999-02-04 2009-05-19 Pluristem Life Systems Inc. Method of expanding undifferentiated hemopoietic stem cells
US20050176137A1 (en) * 1999-02-04 2005-08-11 Technion Research & Development Foundation Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050176143A1 (en) * 1999-02-04 2005-08-11 Technion Research & Development Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2208782A2 (en) 1999-02-04 2010-07-21 Pluristem Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US6440682B1 (en) * 1999-05-28 2002-08-27 Detroit R&D Inc. Detection of hypertension using immunoreactive metabolic products
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20050089939A1 (en) * 1999-06-01 2005-04-28 Jun Tan Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20060019340A1 (en) * 1999-06-08 2006-01-26 David Naor CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US8193311B2 (en) 1999-06-08 2012-06-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20030086914A1 (en) * 1999-06-25 2003-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and device for inducing biological processes by micro-organs
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US20050113327A1 (en) * 1999-08-30 2005-05-26 Levava Roiz Methods of and compositions for inhibiting the proliferation of mammalian cells
US7101839B1 (en) 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US20110008314A1 (en) * 1999-08-30 2011-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US8236543B2 (en) 1999-08-30 2012-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US8735127B2 (en) 1999-08-30 2014-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US8617867B2 (en) 1999-08-30 2013-12-31 Yissum Research Develpment Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US20070292930A1 (en) * 1999-11-19 2007-12-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of producing recombinant Aspergillus niger beta-glucosidase and an aroma spreading plant
US7223902B1 (en) 1999-11-19 2007-05-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US20070264274A1 (en) * 2000-01-05 2007-11-15 Yeda Research And Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US7270810B2 (en) 2000-01-05 2007-09-18 Yeda Research And Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20030211490A1 (en) * 2000-01-24 2003-11-13 Hanan Stein Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US7385106B2 (en) 2000-01-24 2008-06-10 Ramot At Tel Aviv University Ltd. Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
EP2316950A1 (en) 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US9095533B2 (en) 2000-03-27 2015-08-04 Technion Research & Development Foundation Limited Antigen-presenting complex-binding compositions and uses thereof
US20030104491A1 (en) * 2000-04-30 2003-06-05 Cabantchik Ioav Zvi Molecules and methods using same for measuring non-transferrin bound iron
US8088160B2 (en) 2000-07-20 2012-01-03 Multi-Gene Vascular Systems Ltd. (“MGVS”) Drug-eluting intravascular prostheses and methods of use
EP2359853A1 (en) 2000-08-08 2011-08-24 Technion Research and Development Foundation, Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359854A1 (en) 2000-08-08 2011-08-24 Technion Research and Development Foundation, Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1683874A2 (en) 2000-08-29 2006-07-26 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US20070160546A1 (en) * 2000-09-28 2007-07-12 Tamar Lotan Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US20060099273A1 (en) * 2000-09-28 2006-05-11 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US8062660B2 (en) 2000-09-28 2011-11-22 Nanocyte Inc. Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060159769A1 (en) * 2000-09-28 2006-07-20 Nanocyte Inc. Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20070281037A9 (en) * 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20040076976A1 (en) * 2000-11-02 2004-04-22 Pan Shen Quan Aopb gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
US7060462B2 (en) 2000-11-02 2006-06-13 National University Of Singapore AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
EP2186530A1 (en) 2000-11-17 2010-05-19 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
EP2425841A1 (en) 2000-11-24 2012-03-07 Vascular Biogenics Ltd. Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
US20030003464A1 (en) * 2000-11-27 2003-01-02 Phan Brigitte C. Dual bead assays including optical biodiscs and methods relating thereto
US20040248093A1 (en) * 2000-11-27 2004-12-09 Coombs James Howard Magneto-optical bio-discs and systems including related methods
US20020172980A1 (en) * 2000-11-27 2002-11-21 Phan Brigitte Chau Methods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
WO2002044736A2 (en) 2000-11-30 2002-06-06 Molecular Skincare Limited Diagnosis and treatment of epidermal or skin diseases
EP2357478A2 (en) 2000-11-30 2011-08-17 Crawford Healthcare Holdings Limited Diagnosis of disease
US20040052769A1 (en) * 2000-11-30 2004-03-18 Yair Reisner Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20020142287A1 (en) * 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
US7087395B1 (en) 2001-01-16 2006-08-08 Quest Diagnostics Investments Incorporated Vitamin D assay
US20050202098A1 (en) * 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
US20050031618A1 (en) * 2001-01-31 2005-02-10 Dror Mevorach Induction of tolerance by apoptotic and/or necrotic cells
EP2308994A1 (en) 2001-03-23 2011-04-13 Yeda Research And Development Co., Ltd. Methods for determining a risk to develop cancer
US7033747B2 (en) 2001-04-11 2006-04-25 Nagaoka & Co., Ltd Multi-parameter assays including analysis discs and methods relating thereto
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US20050022269A1 (en) * 2001-07-19 2005-01-27 Joseph Hirschberg Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US7442781B2 (en) 2001-08-16 2008-10-28 Urifer Ltd. Diagnosis, prevention and treatment of cancer
US20030064058A1 (en) * 2001-09-07 2003-04-03 Nadir Askenasy Methods of utilizing bone marrow stem cells for inducing immunological tolerance
US7138144B2 (en) 2001-09-07 2006-11-21 Nadir Askenasy Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US8415318B2 (en) 2001-10-19 2013-04-09 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US20100088037A1 (en) * 2001-10-23 2010-04-08 Epipop Pty Ltd. Method for Identification and Development of Therapeutic Agents
US20060257865A1 (en) * 2001-10-23 2006-11-16 Simon Mallal Method for identification and development of therapeutic agents
US6867005B2 (en) 2001-10-24 2005-03-15 Beckman Coulter, Inc. Method and apparatus for increasing the dynamic range and accuracy of binding assays
WO2003046201A2 (en) 2001-11-21 2003-06-05 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
US20060051426A1 (en) * 2001-12-05 2006-03-09 Gershon Golomb Nanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US8178128B2 (en) 2001-12-05 2012-05-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles containing polymeric nucleic acid homologs
US20050085432A1 (en) * 2001-12-26 2005-04-21 Aviva Lapidot Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20050008624A1 (en) * 2002-01-24 2005-01-13 Tony Peled Expansion of renewable stem cell populations
EP2305794A1 (en) 2002-01-24 2011-04-06 Gamida Cell Ltd. Expansion of renewable stem cell populations
US7955852B2 (en) 2002-01-24 2011-06-07 Gamida Cell Ltd. Expansion of renewable stem cell populations
US20110033427A1 (en) * 2002-01-24 2011-02-10 Gamida Cell Ltd. Expansion Of Renewable Stem Cell Populations
US7655225B2 (en) 2002-01-25 2010-02-02 Gamida Cell, Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20080279828A1 (en) * 2002-01-25 2008-11-13 Tony Peled Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20100022459A1 (en) * 2002-01-31 2010-01-28 Tel Aviv University Future Technology Development L.P Peptides directed for diagnosis and treatment of amyloid-associated diseases
US8993510B2 (en) 2002-01-31 2015-03-31 Tel Aviv University Future Technology Development L.P. Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20060234947A1 (en) * 2002-01-31 2006-10-19 Tel Aviv University Future Technology Development L.P Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US8697634B2 (en) 2002-01-31 2014-04-15 Tel Aviv University Future Technology Development L.P. Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US8012929B2 (en) 2002-01-31 2011-09-06 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20100105608A1 (en) * 2002-01-31 2010-04-29 Tel Aviv University Future Technology Development L.P. Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20050287141A1 (en) * 2002-02-13 2005-12-29 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2329814A1 (en) 2002-02-13 2011-06-08 Technion Research and Development Foundation, Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer
EP2072045A2 (en) 2002-02-13 2009-06-24 Technion Research and Development Foundation, Ltd. Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050255101A1 (en) * 2002-02-13 2005-11-17 Technion Research And Development Foundation Ltd. Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20100228007A1 (en) * 2002-02-20 2010-09-09 Technion Research & Development Foundation Ltd. Mhc-peptide complex binding ligands
US20070196369A1 (en) * 2002-02-20 2007-08-23 Hoogenboom Henricus Renerus J MHC-peptide complex binding ligands
US7718777B2 (en) 2002-02-20 2010-05-18 Technion Research & Development Foundation Ltd. MHC-peptide complex binding ligands
EP2508596A2 (en) 2002-02-21 2012-10-10 Bayer Healthcare MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
EP3031910A1 (en) 2002-02-21 2016-06-15 Institute Of Virology Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
US20050220774A1 (en) * 2002-03-18 2005-10-06 Tony Peled Methods of inducing differentiation in ex vivo expanded stem cells
US7611723B2 (en) 2002-03-26 2009-11-03 Nanocyte Inc. Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060039897A1 (en) * 2002-03-26 2006-02-23 Tamar Lotan Stinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20050158809A1 (en) * 2002-04-16 2005-07-21 The Regents Of The University Of Califorina Methods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
US8936914B2 (en) 2002-04-16 2015-01-20 The Regents Of The University Of California Methods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
US20040121442A1 (en) * 2002-05-05 2004-06-24 Ilan Chet Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
EP2561889A2 (en) 2002-08-01 2013-02-27 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2004018698A2 (en) 2002-08-20 2004-03-04 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US8563273B2 (en) 2002-09-06 2013-10-22 Tel Aviv University Future Technology Development L.P. Method of screening for compounds that disaggregate amyloid aggregates
US20090209041A1 (en) * 2002-09-06 2009-08-20 Tel Aviv University Future Technology Development L.P. Peptides and methods for inhibiting amyloid formation
EP2182052A1 (en) 2002-10-07 2010-05-05 Technion Research and Development Foundation, Ltd. Human foreskin cells suitable for culturing stem cells
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
EP2295980A1 (en) 2002-10-30 2011-03-16 Yissum Research Development Company, of The Hebrew University of Jerusalem Molecules and methods using same for measuring non-transferrin bound iron
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US8815823B2 (en) 2002-11-27 2014-08-26 Technion Research & Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US8163494B2 (en) 2002-11-27 2012-04-24 Technion Research & Development Foundation Ltd. Method for assessing metastatic properties of breast cancer
US20060127402A1 (en) * 2002-11-27 2006-06-15 Technion Research & Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2062919A2 (en) 2002-11-27 2009-05-27 Technion Research and Development Foundation, Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2062918A2 (en) 2002-11-27 2009-05-27 Technion Research and Development Foundation, Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US20100119515A1 (en) * 2002-11-27 2010-05-13 Gera Neufeld Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US7947499B2 (en) 2002-11-29 2011-05-24 Technion Research & Development Foundation Ltd. Method of dynamically culturing embryonic stem cells
US20110027887A1 (en) * 2002-11-29 2011-02-03 Technion Research & Development Foundation Ltd. Method of dynamically culturing embryonic stem cells
US20060148078A1 (en) * 2002-11-29 2006-07-06 Sharon Gerecht-Nir Method of dynamically culturing embryonic stem cells
US20090123553A1 (en) * 2002-12-09 2009-05-14 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US8053554B2 (en) 2002-12-09 2011-11-08 Ramot At Tel-Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP2338896A2 (en) 2002-12-12 2011-06-29 R.B.T. (Rakuto Bio Technologies) Ltd. Use of lignin peroxidase in skin and hair lightening
EP2457999A2 (en) 2002-12-16 2012-05-30 Technion Research & Development Foundation Ltd. Culture medium for pluropotent stem cells
EP2292762A2 (en) 2002-12-20 2011-03-09 Board of Regents, The University of Texas System VMP-like sequences of pathogenic Borrelia species and strains
WO2004060135A2 (en) 2003-01-02 2004-07-22 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US8017586B2 (en) 2003-01-07 2011-09-13 Ramot At Tel-Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US20090121709A1 (en) * 2003-01-07 2009-05-14 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating A foreign material and method of manufacturing same
EP2058275A1 (en) 2003-01-07 2009-05-13 Ramot at Tel-Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US20050032126A1 (en) * 2003-03-03 2005-02-10 Coombs James H. Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
EP2319857A2 (en) 2003-03-04 2011-05-11 Yeda Research And Development Co., Ltd. Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
EP2216033A2 (en) 2003-03-06 2010-08-11 Yeda Research and Development Co. Ltd. Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
US7632923B2 (en) 2003-03-26 2009-12-15 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050152912A1 (en) * 2003-03-26 2005-07-14 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20100080805A1 (en) * 2003-03-26 2010-04-01 Technion Research & Development Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US9023348B2 (en) 2003-03-26 2015-05-05 Technion Research & Development Foundation Limited Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US9616112B2 (en) 2003-03-26 2017-04-11 Technion Research & Development Foundation Limited Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060083735A1 (en) * 2003-03-26 2006-04-20 Technion Research & Development Foundation Ltd. Antigen-presenting complex-binding compositions and uses thereof
US7638124B2 (en) 2003-03-26 2009-12-29 Technion Research & Development Foundation Ltd. Antigen-presenting complex-binding compositions and uses thereof
US7294701B2 (en) 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040197334A1 (en) * 2003-04-02 2004-10-07 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
EP2330132A1 (en) 2003-04-04 2011-06-08 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US8252588B2 (en) 2003-04-08 2012-08-28 Yeda Research And Development Co. Ltd. Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
US9463241B2 (en) 2003-04-09 2016-10-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for stabilising an immunoglobulin G composition in liquid form
US8388954B2 (en) 2003-04-09 2013-03-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
US20060035980A1 (en) * 2003-04-18 2006-02-16 Scanlan Thomas S Thyronamine derivatives and analogs and methods of use thereof
US7355079B2 (en) 2003-04-18 2008-04-08 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
US7554007B2 (en) 2003-05-22 2009-06-30 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants
US20060123516A1 (en) * 2003-05-22 2006-06-08 Gil Ronen Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US8481812B2 (en) 2003-05-22 2013-07-09 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants generated thereby
EP2365087A2 (en) 2003-05-22 2011-09-14 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US9303269B2 (en) 2003-05-22 2016-04-05 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants
US20090260109A1 (en) * 2003-05-22 2009-10-15 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants genterated thereby
US9567579B2 (en) 2003-05-23 2017-02-14 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
US20050020499A1 (en) * 2003-05-27 2005-01-27 Bar Ilan University Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20060260002A1 (en) * 2003-06-19 2006-11-16 Gil Ronen Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20090253170A1 (en) * 2003-06-19 2009-10-08 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US8129514B2 (en) 2003-06-19 2012-03-06 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7498428B2 (en) 2003-06-19 2009-03-03 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
EP2719394A1 (en) 2003-06-30 2014-04-16 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases
US20110229495A1 (en) * 2003-07-07 2011-09-22 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
EP2540302A1 (en) 2003-07-15 2013-01-02 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP2526952A1 (en) 2003-07-15 2012-11-28 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP2540301A2 (en) 2003-07-15 2013-01-02 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
EP2526953A1 (en) 2003-07-15 2012-11-28 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20050271643A1 (en) * 2003-08-14 2005-12-08 Iryna Sorokulova Bacterial strains, compositions including same and probiotic use thereof
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
WO2005033142A2 (en) 2003-10-07 2005-04-14 Yeda Research And Development Co. Ltd. Anti-nik antibodies and uses thereof
WO2005033145A1 (en) 2003-10-07 2005-04-14 Yeda Research And Development Co. Ltd. Antibodies to nik, their preparation and use
EP2354164A1 (en) 2003-10-07 2011-08-10 Yeda Research And Development Co., Ltd. Anti-NIK antibodies and uses thereof
EP2322561A1 (en) 2003-10-07 2011-05-18 Yeda Research And Development Co., Ltd. Anti-NIK antibodies and uses thereof
US20060257429A1 (en) * 2003-10-23 2006-11-16 Dreier Kimberly J Vaccine for periodontal disease
EP2243491A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
EP2149585A1 (en) 2003-11-04 2010-02-03 Novartis Vaccines and Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
EP2248830A1 (en) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP2301575A1 (en) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
EP2243492A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005051423A2 (en) 2003-11-30 2005-06-09 Yeda Research And Development Co. Ltd Methods and agents for immune modulation and methods for identifying immune modulators
US7790673B2 (en) 2003-12-12 2010-09-07 New York University Methods and compositions relating to cystatin C
US20070032421A1 (en) * 2003-12-12 2007-02-08 Efrat Levy Methods and compositions relating to cystatin C
US20100221233A1 (en) * 2003-12-15 2010-09-02 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
EP2289567A2 (en) 2003-12-22 2011-03-02 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US20060278093A1 (en) * 2004-01-13 2006-12-14 Eytan Biderman Feeding formula appliance
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US7893240B2 (en) 2004-01-20 2011-02-22 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050158822A1 (en) * 2004-01-20 2005-07-21 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20080312179A1 (en) * 2004-01-20 2008-12-18 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20110091454A1 (en) * 2004-01-27 2011-04-21 Alex Diber Methods and systems for annotating biomolecular sequences
EP3006039A1 (en) 2004-03-02 2016-04-13 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
US20090126042A1 (en) * 2004-06-14 2009-05-14 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2336330A2 (en) 2004-06-14 2011-06-22 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20100281571A1 (en) * 2004-06-14 2010-11-04 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US9012728B2 (en) 2004-06-14 2015-04-21 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2343373A1 (en) 2004-06-14 2011-07-13 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8962915B2 (en) 2004-06-14 2015-02-24 Evogene Ltd. Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US20080004234A1 (en) * 2004-07-06 2008-01-03 Segev Laboratories Limited System for delivering therapeutic agents into living cells and cells nuclei
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
US20110201035A1 (en) * 2004-09-08 2011-08-18 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Compositions and methods for the detection of hiv-1/hiv-2 infection
US7888003B2 (en) 2004-09-08 2011-02-15 The United States Of America As Represented By The Department Of Health And Human Services Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
EP2295973A1 (en) 2004-09-08 2011-03-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for the detection of HIV-1/HIV-2 infection.
EP2295974A1 (en) 2004-09-08 2011-03-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for the detection of HIV-1/HIV-2 infection
US20110151436A1 (en) * 2004-09-08 2011-06-23 The Government of the United States of America as represented by the Secretary, Dept. of Health Compositions and methods for the detection of hiv-1/hiv-2 infection
US8722324B2 (en) 2004-09-08 2014-05-13 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
EP2309269A1 (en) 2004-09-08 2011-04-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for the detection of HIV-1/HIV-2 infection.
US9121855B2 (en) 2004-09-08 2015-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
US8080417B2 (en) 2004-09-16 2011-12-20 Gamida-Cell Ltd. Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
US20070077652A1 (en) * 2004-09-16 2007-04-05 Tony Peled Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
EP3088528A1 (en) 2004-09-29 2016-11-02 Collplant Ltd. Collagen producing plants and methods of generating and using same
US8039240B2 (en) 2004-09-29 2011-10-18 Yissum Reseach Development Company Of The Hebrew University Of Jerusalem Recombinant human T2 RNase and uses thereof
EP2816117A2 (en) 2004-09-29 2014-12-24 Collplant Ltd. Collagen producing plants and methods of generating and using same
US20080131419A1 (en) * 2004-09-29 2008-06-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant Human T2 Rnase and Uses Thereof
US7781402B2 (en) 2004-10-12 2010-08-24 Closed Loop Therapies Ltd. Methods and implantable devices for treating supraventricular arrhythmias
US20060079941A1 (en) * 2004-10-12 2006-04-13 Eli Ovsyshcher Methods and implantable devices for treating supraventricular arrhythmias
US20110040248A1 (en) * 2004-10-12 2011-02-17 Closed Loop Therapies Bv Methods and implantable devices for treating supraventricular arrhythmias
US20060095241A1 (en) * 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060190226A1 (en) * 2004-10-29 2006-08-24 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20090118132A1 (en) * 2004-11-04 2009-05-07 Roche Molecular Systems, Inc. Classification of Acute Myeloid Leukemia
EP2174668A2 (en) 2004-11-14 2010-04-14 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20060134680A1 (en) * 2004-12-22 2006-06-22 Alexander Kotlyar Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20080216022A1 (en) * 2005-01-16 2008-09-04 Zlango Ltd. Iconic Communication
US20080082678A1 (en) * 2005-01-16 2008-04-03 Zlango Ltd. Communications Network System and Methods for Using Same
US8375327B2 (en) 2005-01-16 2013-02-12 Zlango Ltd. Iconic communication
US8019818B2 (en) 2005-01-18 2011-09-13 Zlango Ltd. Communications network system and methods for using same
US20090013087A1 (en) * 2005-01-18 2009-01-08 Zlango Ltd. Communications Network System and Methods For Using Same
EP2316441A1 (en) 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
WO2006090388A2 (en) 2005-02-25 2006-08-31 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Fruit cell culture extract for treating inflammation
US20060211064A1 (en) * 2005-03-18 2006-09-21 Hyesook Kim Detection of hypertension using glucuronidated metabolic products
US7695927B2 (en) 2005-03-18 2010-04-13 Detroit R & D Detection of hypertension using glucuronidated metabolic products
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US8834862B2 (en) 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060234203A1 (en) * 2005-04-19 2006-10-19 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US9567568B2 (en) 2005-05-04 2017-02-14 Enlivex Therapeutics Ltd. Method of preparing apoptotic monocytes
EP2312315A1 (en) 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
EP2279726A2 (en) 2005-05-26 2011-02-02 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP2465924A2 (en) 2005-06-16 2012-06-20 Ramot at Tel-Aviv University Ltd. Isolated cells and populations comprising same for the treament of cns diseases
WO2006134602A2 (en) 2005-06-16 2006-12-21 Ramot At Tel Aviv University Ltd. Isolated cells and populations comprising same for the treatment of cns diseases
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20060292559A1 (en) * 2005-06-23 2006-12-28 Beckman Coulter, Inc. Cell-based microarrays, and methods for their preparation and use
EP2487182A2 (en) 2005-07-07 2012-08-15 FULCRUM SP Ltd. SP1 polypeptides, modified SP1 polypeptides and uses thereof
US20090143321A1 (en) * 2005-07-07 2009-06-04 Avraham Hochberg Nucleic acid agents for downregulating h19 and methods of using same
US8067574B2 (en) 2005-07-07 2011-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19, and methods of using same
US8067573B2 (en) 2005-07-07 2011-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19 and methods of using same
EP2484768A2 (en) 2005-07-18 2012-08-08 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
EP2441840A1 (en) 2005-07-18 2012-04-18 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
EP2889041A1 (en) 2005-07-26 2015-07-01 Rutgers, The State University of New Jersey Kit of reagents for tuberculosis assay
US8642330B2 (en) 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20100068135A1 (en) * 2005-08-08 2010-03-18 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20110126323A1 (en) * 2005-08-15 2011-05-26 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20090089898A1 (en) * 2005-08-15 2009-04-02 Hagai Karchi Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007020638A2 (en) 2005-08-15 2007-02-22 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US9487796B2 (en) 2005-08-15 2016-11-08 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2995194A1 (en) 2005-08-15 2016-03-16 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US7910800B2 (en) 2005-08-15 2011-03-22 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A2 (en) 2005-08-24 2007-03-01 Yeda Research And Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP2514315A2 (en) 2005-08-24 2012-10-24 Yeda Research and Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007031996A1 (en) 2005-09-12 2007-03-22 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
US20090221681A1 (en) * 2005-09-22 2009-09-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2007034487A1 (en) 2005-09-22 2007-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US8034914B2 (en) 2005-09-22 2011-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
EP2716654A1 (en) 2005-10-24 2014-04-09 Evogene Ltd. Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2390312A1 (en) 2005-11-29 2011-11-30 Gamida Cell Ltd. Methods of improving stem cell homing and engraftment
US8775526B2 (en) 2006-01-16 2014-07-08 Zlango Ltd. Iconic communication
EP2368570A2 (en) 2006-01-18 2011-09-28 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2368569A2 (en) 2006-01-18 2011-09-28 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8323636B2 (en) 2006-02-03 2012-12-04 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2532675A1 (en) 2006-02-03 2012-12-12 Modigene Inc Long-acting polypeptides and methods of producing and administering same
US9828417B2 (en) 2006-02-03 2017-11-28 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20070184530A1 (en) * 2006-02-03 2007-08-09 Fuad Fares Long-acting veterinary polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
EP2853541A1 (en) 2006-02-03 2015-04-01 OPKO Biologics Ltd. Long-acting polypeptides and uses thereof
US8465948B2 (en) 2006-02-03 2013-06-18 Prolor Biotech Ltd. Long-acting veterinary polypeptides and methods of producing and administering same
EP3202779A2 (en) 2006-02-03 2017-08-09 OPKO Biologics Ltd. Long-acting hgh polypeptides and uses thereof
WO2007094985A2 (en) 2006-02-03 2007-08-23 Modigene Inc Long-acting polypeptides and methods of producing and administering same
US20070190610A1 (en) * 2006-02-03 2007-08-16 Fuad Fares Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20070190611A1 (en) * 2006-02-03 2007-08-16 Fuad Fares Long-acting polypeptides and methods of producing same
EP2853536A1 (en) 2006-02-03 2015-04-01 OPKO Biologics Ltd. Long-acting erythropoietin polypeptides and uses thereof
EP2532674A1 (en) 2006-02-03 2012-12-12 Modigene Inc Long-acting polypeptides and methods of producing and administering same
US8999670B2 (en) 2006-02-03 2015-04-07 Opko Biologics Ltd. Long-acting polypeptides and methods of producing same
US8426166B2 (en) 2006-02-03 2013-04-23 Prolor Biotech Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
EP2471807A1 (en) 2006-02-03 2012-07-04 Modigene Inc Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2007091254A1 (en) 2006-02-06 2007-08-16 Rappaport Family Institute For Research In The Medical Sciences Methods and kit for diagnosing t1dm
US9057092B2 (en) 2006-03-06 2015-06-16 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
EP2548951A1 (en) 2006-03-23 2013-01-23 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2366775A1 (en) 2006-03-23 2011-09-21 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2626417A1 (en) 2006-03-23 2013-08-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP3091071A1 (en) 2006-03-23 2016-11-09 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
WO2007110869A2 (en) 2006-03-28 2007-10-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to warfarin resistance
US20100055033A1 (en) * 2006-04-07 2010-03-04 The Government Of The United States Of America As Represented By The Secretary Antibody compositions and methods for treatment of neoplastic disease
US8071323B2 (en) 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20110150874A1 (en) * 2006-05-19 2011-06-23 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
US20070281883A1 (en) * 2006-06-05 2007-12-06 Hanna Rosenfeld Development of follicle stimulating hormone agonists and antagonists in fish
WO2008010228A2 (en) 2006-07-20 2008-01-24 Yeda Research And Development Co. Ltd. Photosyntheticorganisms and compositions and methods of generating same
WO2008026198A2 (en) 2006-08-28 2008-03-06 Yeda Research And Development Co. Ltd. Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US8158371B2 (en) 2006-09-08 2012-04-17 Wisconsin Alumni Research Foundation Assay for antibodies to Mycobacterium paratuberculosis
US20110027812A1 (en) * 2006-09-08 2011-02-03 Wisconsin Alumni Research Foundation Assay for antibodies to mycobacterium paratuberculosis
US20080138840A1 (en) * 2006-09-08 2008-06-12 Collins Michael T Assay for antibodies to mycobacterium paratuberculosis
US20080199895A1 (en) * 2006-10-05 2008-08-21 Yeda Research And Development Co. Ltd. Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
WO2008041183A2 (en) 2006-10-05 2008-04-10 Technion Research & Development Foundation Ltd. Microtubes and methods of producing same
US20090293146A1 (en) * 2006-12-20 2009-11-26 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2383345A1 (en) 2006-12-20 2011-11-02 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US9631000B2 (en) 2006-12-20 2017-04-25 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8168857B2 (en) 2006-12-20 2012-05-01 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2860189A2 (en) 2007-01-04 2015-04-15 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
EP2487187A2 (en) 2007-01-04 2012-08-15 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
WO2008084410A2 (en) 2007-01-04 2008-07-17 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US20100105759A1 (en) * 2007-01-16 2010-04-29 Abraham Hochberg H19 silencing nucleic acid agents for treating rheumatoid arthritis
US7928083B2 (en) 2007-01-16 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
WO2008093341A2 (en) 2007-01-31 2008-08-07 Technion Research & Development Foundation Ltd. Electrospun scaffolds and methods of generating and using same
WO2008093342A2 (en) 2007-02-01 2008-08-07 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
EP2478924A1 (en) 2007-02-01 2012-07-25 Technion Research & Development Foundation Albumin fibers and fabrics and methods of generating and using same
US8586052B2 (en) 2007-02-02 2013-11-19 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US9453074B2 (en) 2007-02-02 2016-09-27 Baylor Research Institute Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
EP2684889A2 (en) 2007-02-02 2014-01-15 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
US9234040B2 (en) 2007-02-02 2016-01-12 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US8057798B2 (en) 2007-02-02 2011-11-15 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US8236934B2 (en) 2007-02-02 2012-08-07 Baylore Research Institute Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US9102730B2 (en) 2007-02-02 2015-08-11 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US20080241170A1 (en) * 2007-02-02 2008-10-02 Baylor Research Institute Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells
US20080206262A1 (en) * 2007-02-02 2008-08-28 Baylor Research Institute Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR)
US8728481B2 (en) 2007-02-02 2014-05-20 Baylor Research Institute Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
EP2527363A1 (en) 2007-02-02 2012-11-28 Baylor Research Institute Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells
US8449888B2 (en) 2007-02-02 2013-05-28 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US20100330115A1 (en) * 2007-02-02 2010-12-30 Baylor Research Institute Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
WO2008097870A2 (en) 2007-02-02 2008-08-14 Baylor Research Institute Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc- asgpr)
US20080254044A1 (en) * 2007-02-02 2008-10-16 Baylor Research Institute Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
US7786267B2 (en) 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
US20080254047A1 (en) * 2007-02-23 2008-10-16 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through CLEC-6
EP2522718A1 (en) 2007-02-23 2012-11-14 Baylor Research Institute Therapeutic applications of activation of human antigen-presenting cells through dectin-1
US20080233140A1 (en) * 2007-02-23 2008-09-25 Baylor Research Institute Therapeutic Applications of Activation of Human Antigen-Presenting Cells Through Dectin-1
US9339556B2 (en) 2007-02-23 2016-05-17 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
US20080267984A1 (en) * 2007-02-23 2008-10-30 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1)
US8481314B2 (en) 2007-02-23 2013-07-09 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
EP2839839A1 (en) 2007-02-28 2015-02-25 Yeda Research And Development Company Limited Nuclear targeting sequences
EP2514766A2 (en) 2007-03-29 2012-10-24 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120202A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A1 (en) 2007-04-02 2008-10-09 Ramot At Tel Aviv University Ltd. Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
US20100154077A1 (en) * 2007-04-09 2010-06-17 Evogene Ltd. Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US8513488B2 (en) 2007-04-09 2013-08-20 Evogene Ltd. Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US9487793B2 (en) 2007-04-09 2016-11-08 Evogene Ltd. Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US8293209B2 (en) 2007-04-23 2012-10-23 Segev Laboratories Limited System for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
US20100092386A1 (en) * 2007-04-23 2010-04-15 David Segev System for delivering therapeutic agents into living cells and cells nuclei
WO2008132753A2 (en) 2007-05-01 2008-11-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for detecting fetal cells in the maternal blood
EP3032259A1 (en) 2007-05-01 2016-06-15 Tel Hashomer Medical Research Infrastructure and Services Ltd. Methods for detecting trophoblast cells in maternal blood based on cytokeratin-7
EP2529754A1 (en) 2007-05-03 2012-12-05 Agency For Science, Technology And Research (A*star) Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP2500428A2 (en) 2007-07-11 2012-09-19 Yeda Research and Development Co. Ltd. Nucleic acid construct systems capable of diagnosing or treating a cell state
EP3075854A1 (en) 2007-07-15 2016-10-05 Technion Research & Development Foundation Ltd. Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP2527441A2 (en) 2007-07-15 2012-11-28 Technion Research & Development Foundation Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
WO2009010968A2 (en) 2007-07-15 2009-01-22 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US20100319088A1 (en) * 2007-07-24 2010-12-16 Gil Ronen Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2910638A2 (en) 2007-07-24 2015-08-26 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US9518267B2 (en) 2007-07-24 2016-12-13 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US8686227B2 (en) 2007-07-24 2014-04-01 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US20090053224A1 (en) * 2007-08-02 2009-02-26 Arresto Biosciences Lox and loxl2 inhibitors and uses thereof
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8658167B2 (en) 2007-08-02 2014-02-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US20090104201A1 (en) * 2007-08-02 2009-04-23 Victoria Smith Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8679485B2 (en) 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
EP2581445A1 (en) 2007-08-15 2013-04-17 Yeda Research And Development Co. Ltd. Regulators of MMP-9 and uses thereof
US20090068669A1 (en) * 2007-09-12 2009-03-12 Elias Georges Slc9a3r1 directed diagnostics for neoplastic disease
WO2009034574A2 (en) 2007-09-12 2009-03-19 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
EP3103463A1 (en) 2007-09-19 2016-12-14 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2591789A2 (en) 2007-09-19 2013-05-15 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2050826A2 (en) 2007-10-16 2009-04-22 Roche Diagnostics GmbH Reagents and methods for detecting neisseria gonorrhoeae
EP2781223A1 (en) 2007-10-19 2014-09-24 Rappaport Family Institute for Research in the Medical Sciences Compositions comprising semaphorins for the treatment of angiogenesis related diseases
US20110177112A1 (en) * 2007-11-02 2011-07-21 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papilloma virus infection
US9138470B2 (en) 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
EP2599790A1 (en) 2007-11-26 2013-06-05 Yissum Research Development Company of The Hebrew University of Jerusalem Compositions comprising fibrous polypeptides and polysachharides
EP2071021A2 (en) 2007-12-12 2009-06-17 University of South Florida Bone marrow-derived neuronal cells
WO2009083958A2 (en) 2007-12-27 2009-07-09 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US9670501B2 (en) 2007-12-27 2017-06-06 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US8426682B2 (en) 2007-12-27 2013-04-23 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009104174A2 (en) 2008-02-21 2009-08-27 Technion Research & Development Foundation Ltd . A method of attaching a cell-of-interest to a microtube
US20090305302A1 (en) * 2008-03-18 2009-12-10 Collins Michael T Mycobacterial culture screening test for mycobacterium avium complex bacteria
US8153383B2 (en) 2008-03-18 2012-04-10 Wisconsin Alumni Research Foundation Mycobacterial culture screening test for Mycobacterium avium complex bacteria
US20110033473A1 (en) * 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
US8747855B2 (en) 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
US20110020357A1 (en) * 2008-04-09 2011-01-27 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
US20110147993A1 (en) * 2008-04-10 2011-06-23 Objet Geometries Ltd. System and method for three dimensional model printing
US9132587B2 (en) 2008-04-10 2015-09-15 Stratasys Ltd. System and method for three dimensional model printing
EP3020410A1 (en) 2008-04-18 2016-05-18 Collplant Ltd. Methods of generating and using procollagen
EP2936976A1 (en) 2008-04-21 2015-10-28 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
US20110097771A1 (en) * 2008-05-22 2011-04-28 Eyal Emmanuel Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
US8847008B2 (en) 2008-05-22 2014-09-30 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
EP2620493A1 (en) 2008-05-28 2013-07-31 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
US20100135994A1 (en) * 2008-07-16 2010-06-03 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
EP3009449A1 (en) 2008-07-16 2016-04-20 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US9109011B2 (en) 2008-07-16 2015-08-18 Baylor Research Institute Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
EP3178845A1 (en) 2008-07-16 2017-06-14 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP2960250A1 (en) 2008-07-16 2015-12-30 Institute for Research in Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
EP2966091A1 (en) 2008-07-16 2016-01-13 Baylor Research Institute Agonistic anti-cd40 antibodies
US20100080813A1 (en) * 2008-07-25 2010-04-01 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US20100086555A1 (en) * 2008-07-25 2010-04-08 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8685402B2 (en) 2008-07-25 2014-04-01 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
US9340603B2 (en) 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010016806A1 (en) 2008-08-08 2010-02-11 Agency For Science, Technology And Research (A*Star) Vhz for diagnosis and treatment of cancers
EP2657342A1 (en) 2008-08-08 2013-10-30 Genisphere Inc. DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA
WO2010017544A2 (en) 2008-08-08 2010-02-11 Genisphere, Inc. Long-acting dna dendrimers and methods thereof
US20110145946A1 (en) * 2008-08-18 2011-06-16 Evogene Ltd. Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
US9018445B2 (en) 2008-08-18 2015-04-28 Evogene Ltd. Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
EP3072972A2 (en) 2008-08-18 2016-09-28 Evogene Ltd. Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
EP3115451A1 (en) 2008-09-02 2017-01-11 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
US8367392B2 (en) 2008-09-05 2013-02-05 Transalgae Ltd. Genetic transformation of algal and cyanobacteria cells by microporation
US20100081177A1 (en) * 2008-09-05 2010-04-01 TransAlgae Ltd Decreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
WO2010029545A2 (en) 2008-09-11 2010-03-18 Ben Gurion University Of The Negev Research And Development Authority Compositions and methods for treating s. pneumoniae infection
WO2010031006A1 (en) 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Ischemic tissue cell therapy
EP2789626A2 (en) 2008-09-24 2014-10-15 Tel Hashomer Medical Research Infrastructure and Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010035261A2 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US8921658B2 (en) 2008-10-30 2014-12-30 Evogene Ltd. Isolated polynucleotides encoding a MAP65 polypeptide and methods of using same for increasing plant yield
US20110197315A1 (en) * 2008-10-30 2011-08-11 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield
WO2010049897A2 (en) 2008-10-30 2010-05-06 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
WO2010055525A1 (en) 2008-11-17 2010-05-20 Technion Research & Development Foundation Ltd. Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A1 (en) 2008-11-26 2010-06-03 Biodalia Microbiological Technologies Ltd. A method of in-situ enrichment of foods with fructan
WO2010064231A1 (en) 2008-12-02 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A1 (en) 2008-12-03 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to cancer
EP2633854A1 (en) 2008-12-05 2013-09-04 Yeda Research And Development Co. Ltd. miRNA-9 or miRNA-9* for use in treating MND
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
WO2010076642A1 (en) 2008-12-29 2010-07-08 Tel Hashomer Medical Research, Infrastructure And Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010076788A2 (en) 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076756A2 (en) 2008-12-29 2010-07-08 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
EP2808402A2 (en) 2008-12-29 2014-12-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment
EP3244189A1 (en) 2008-12-30 2017-11-15 Jin Po Lee Quantitative analyte assay device and method
WO2010076794A1 (en) 2008-12-31 2010-07-08 Technion Research & Development Foundation Ltd. Method of denitrifying brine and systems capable of same
US20100209415A1 (en) * 2009-01-06 2010-08-19 Victoria Smith Chemotherapeutic methods and compositions
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2010086856A2 (en) 2009-02-01 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A2 (en) 2009-02-02 2010-08-05 Ramot At Tel Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A1 (en) 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010097794A1 (en) 2009-02-26 2010-09-02 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of reprogramming renal cells
EP2465920A2 (en) 2009-02-26 2012-06-20 Tel HaShomer Medical Research Infrastructure and Services Ltd. Isolated populations of renal stem cells and methods of isolating and using same
WO2010097793A2 (en) 2009-02-26 2010-09-02 Tel Hashomer Medical Research Infrastructure And Services Ltd. Isolated populations of renal stem cells and methods of isolating and using same
WO2010100595A2 (en) 2009-03-02 2010-09-10 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
US8937220B2 (en) 2009-03-02 2015-01-20 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield, biomass, vigor and/or growth rate of a plant
EP3000889A2 (en) 2009-03-02 2016-03-30 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
EP3026057A2 (en) 2009-03-09 2016-06-01 Ramot at Tel Aviv University Ltd. Compositions for prevention and treatment of neurodegenerative diseases
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A1 (en) 2009-04-01 2010-10-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
US9212219B2 (en) 2009-04-03 2015-12-15 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
EP3002293A1 (en) 2009-04-03 2016-04-06 The University of Chicago Compositions and methods related to protein a (spa) variants
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
EP2990421A1 (en) 2009-04-30 2016-03-02 Tel HaShomer Medical Research Infrastructure and Services Ltd. Anti ceacam1 antibodies and methods of using same
US9182403B2 (en) 2009-05-19 2015-11-10 Zetiq Technologies Ltd. Kits for and methods of differential staining of cervical cancer cells and/or tissues
WO2010135663A2 (en) 2009-05-21 2010-11-25 The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2010137021A2 (en) 2009-05-27 2010-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue
WO2010137017A2 (en) 2009-05-27 2010-12-02 Yeda Research And Development Co. Ltd. Proteasome inhibitors and uses thereof
WO2010137013A1 (en) 2009-05-27 2010-12-02 Ramot At Tel Aviv University Ltd. Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137020A1 (en) 2009-05-28 2010-12-02 Yeda Research And Development Co. Ltd. Methods of treating inflammation
EP3238534A2 (en) 2009-06-10 2017-11-01 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
US9096865B2 (en) 2009-06-10 2015-08-04 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2010150259A1 (en) 2009-06-24 2010-12-29 Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical Center Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
EP3130346A1 (en) 2009-07-09 2017-02-15 OPKO Biologics Ltd. Long-acting factor vii coagulation factors
WO2011004361A2 (en) 2009-07-09 2011-01-13 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
WO2011010309A1 (en) 2009-07-21 2011-01-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. A method of diagnosing cancer
US9574210B2 (en) 2009-07-31 2017-02-21 Ramot At Tel-Aviv University Ltd. Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011013130A2 (en) 2009-07-31 2011-02-03 Ramot At Tel-Aviv University Ltd. Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011021194A2 (en) 2009-08-17 2011-02-24 Technion Research & Development Foundation Ltd. Pericyte progenitor cells and methods of generating and using same
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
US20110076272A1 (en) * 2009-08-21 2011-03-31 Victoria Smith Therapeutic methods and compositions
US8512990B2 (en) 2009-08-21 2013-08-20 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US20110076739A1 (en) * 2009-08-21 2011-03-31 Mccauley Scott Catalytic domains from lysyl oxidase and loxl2
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US20110044981A1 (en) * 2009-08-21 2011-02-24 Spangler Rhyannon Methods and compositions for treatment of pulmonary fibrotic disorders
WO2011021171A1 (en) 2009-08-21 2011-02-24 Beeologics, Llc Preventing and curing beneficial insect diseases via plant transcribed molecules
WO2011024172A2 (en) 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
WO2011030332A2 (en) 2009-09-08 2011-03-17 Yeda Research And Development Co. Ltd. Methods for hematopoietic precursor mobilization
WO2011030336A1 (en) 2009-09-08 2011-03-17 Ramot At Tel-Aviv University Ltd. Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
WO2011033511A1 (en) 2009-09-17 2011-03-24 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011033506A2 (en) 2009-09-17 2011-03-24 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
US20110081706A1 (en) * 2009-10-02 2011-04-07 TransAlgae Ltd Method and system for efficient harvesting of microalgae and cyanobacteria
WO2011045796A1 (en) 2009-10-14 2011-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for controlling varroa mites in bees
WO2011046570A1 (en) 2009-10-16 2011-04-21 The University Of Medicine And Dentistry Of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
WO2011055366A1 (en) 2009-11-08 2011-05-12 Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of Israel Mo-1 conditional knock-out non-human animal and uses thereof
WO2011058557A1 (en) 2009-11-12 2011-05-19 Ramot At Tel-Aviv University Ltd. Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
WO2011063198A2 (en) 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011064773A1 (en) 2009-11-24 2011-06-03 Collplant Ltd. Method of generating collagen fibers
EP2977445A2 (en) 2009-11-30 2016-01-27 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
WO2011064669A2 (en) 2009-11-30 2011-06-03 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
EP2806023A2 (en) 2009-11-30 2014-11-26 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
US9562235B2 (en) 2009-12-06 2017-02-07 A.B. Seeds Ltd. MicroRNA compositions and methods for enhancing plant resistance to abiotic stress
WO2011067745A2 (en) 2009-12-06 2011-06-09 Rosetta Green Ltd. Compositions and methods for enhancing plants resistance to abiotic stress
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
EP2862929A1 (en) 2009-12-09 2015-04-22 Quark Pharmaceuticals, Inc. Compositions and methods for treating diseases, disorders or injury of the CNS
US9493785B2 (en) 2009-12-28 2016-11-15 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
EP3056569A2 (en) 2009-12-28 2016-08-17 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080674A2 (en) 2009-12-28 2011-07-07 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080740A1 (en) 2009-12-29 2011-07-07 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
EP3184109A1 (en) 2009-12-29 2017-06-28 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
EP3159405A1 (en) 2010-01-05 2017-04-26 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
WO2011086509A1 (en) 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
EP3216805A1 (en) 2010-01-27 2017-09-13 Yeda Research and Development Co. Ltd Antibodies that inhibit metalloproteins
WO2011092700A1 (en) 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2011099006A2 (en) 2010-02-11 2011-08-18 Yeda Research And Development Co. Ltd. Enzymatic systems for carbon fixation and methods of generating same
WO2011104708A2 (en) 2010-02-24 2011-09-01 Ben Gurion University Of The Negev Research And Development Authority Methods for inhibiting necrosis
WO2011107939A1 (en) 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en) 2010-03-04 2011-09-09 Yeda Research And Development Co. Ltd. Methods of measuring protein stability
WO2011111034A1 (en) 2010-03-08 2011-09-15 Yeda Research And Development Co. Ltd. Recombinant protein production in heterologous systems
US9121022B2 (en) 2010-03-08 2015-09-01 Monsanto Technology Llc Method for controlling herbicide-resistant plants
WO2011111050A2 (en) 2010-03-11 2011-09-15 Jacob Edrei Methods of generating hydrogen
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
US9458438B2 (en) 2010-04-12 2016-10-04 Ben Gurion University Of The Negev Research And Development Authority Sulfotransferase of a red microalga and uses thereof
WO2011132182A1 (en) 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US9328353B2 (en) 2010-04-28 2016-05-03 Evogene Ltd. Isolated polynucleotides and polypeptides for increasing plant yield and/or agricultural characteristics
WO2011135527A2 (en) 2010-04-28 2011-11-03 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2011138778A2 (en) 2010-05-04 2011-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A2 (en) 2010-05-05 2011-11-10 Rappaport Family Institute For Research In The Medical Sciences Use of ccl1 in therapy
WO2011138776A2 (en) 2010-05-06 2011-11-10 Hervana Ltd. Biologic female contraceptives
WO2011141914A1 (en) 2010-05-13 2011-11-17 Tel Hashomer Medical Research Infrastructure And Services Ltd. Isolated populations of adult renal cells and methods of isolating and using same
WO2011151833A1 (en) 2010-06-03 2011-12-08 Ramot At Tel-Aviv University Ltd. Methods of treating diabetes and compositions capable of same
WO2011154940A1 (en) 2010-06-07 2011-12-15 Osnat Ashur-Fabian Methods and kits for diagnosing conditions related to hypoxia
WO2011158243A2 (en) 2010-06-16 2011-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of diagnosing and treating cancer
WO2011158242A2 (en) 2010-06-16 2011-12-22 Futuragene Israel Ltd. Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2012003474A2 (en) 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants
WO2012007950A2 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007919A2 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007951A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
WO2012014207A2 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014205A1 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014208A2 (en) 2010-07-27 2012-02-02 Yeda Research And Development Co. Ltd. Methods and systems for assessing clonality of cell cultures
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012025914A1 (en) 2010-08-22 2012-03-01 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
WO2012032510A1 (en) 2010-09-07 2012-03-15 Yeda Research And Development Co. Ltd. Primers for amplifying dna and methods of selecting same
WO2012032521A2 (en) 2010-09-07 2012-03-15 Technion Research & Development Foundation Ltd. Novel methods and culture media for culturing pluripotent stem cells
WO2012032520A1 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032519A2 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing parkinson's disease
WO2012032525A2 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. An immunosuppressive drug combination for a stable and long term engraftment
WO2012032526A2 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012034067A1 (en) 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012035539A1 (en) 2010-09-15 2012-03-22 Ramot At Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
WO2012038956A1 (en) 2010-09-20 2012-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
WO2012052872A2 (en) 2010-10-17 2012-04-26 Yeda Research And Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
EP3075396A1 (en) 2010-10-17 2016-10-05 Yeda Research and Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012056452A2 (en) 2010-10-27 2012-05-03 Nanocyte (Israel) Ltd. Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1 (en) 2010-10-28 2012-05-03 Yeda Research And Development Co. Ltd. Methods of generating antibodies to metalloenzymes
WO2012059922A2 (en) 2010-11-03 2012-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Transgenic plants with improved saccharification yields and methods of generating same
WO2012059925A2 (en) 2010-11-04 2012-05-10 Ben-Gurion University Of The Negev Research And Development Authority Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
US9096645B2 (en) 2010-11-15 2015-08-04 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9630989B2 (en) 2010-11-15 2017-04-25 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2012066495A2 (en) 2010-11-17 2012-05-24 Ben Gurion University Of The Negev Research And Development Authority T-cell therapy to neurodegenerative diseases
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
EP2463382A1 (en) 2010-12-07 2012-06-13 Enterologics, Inc. Method for identifying E. Coli M-17
WO2012081029A1 (en) 2010-12-15 2012-06-21 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
US9551006B2 (en) 2010-12-22 2017-01-24 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
WO2012090205A2 (en) 2010-12-28 2012-07-05 Kamedis Ltd. Plant extracts for the treatment and prevention of infections
WO2012098537A1 (en) 2011-01-20 2012-07-26 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012104851A1 (en) 2011-01-31 2012-08-09 Yeda Research And Development Co. Ltd. Methods of diagnosing disease using overlap extension pcr
WO2012114339A1 (en) 2011-02-23 2012-08-30 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012113921A1 (en) 2011-02-25 2012-08-30 Laboratorios Del Dr. Esteve, S.A. Rapid selection method for hiv gp-120 variants
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
WO2012117406A2 (en) 2011-03-02 2012-09-07 Futuragene Israel Ltd. Bacterial resistant transgenic plants
WO2012117373A1 (en) 2011-03-03 2012-09-07 Ramot At Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012120518A1 (en) 2011-03-08 2012-09-13 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012123949A1 (en) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012123938A1 (en) 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
WO2012127320A1 (en) 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
WO2012127475A1 (en) 2011-03-24 2012-09-27 Neurim Pharmaceuticals (1991) Ltd. Neuroprotective peptides
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
WO2012137202A1 (en) 2011-04-05 2012-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9676846B2 (en) 2011-04-12 2017-06-13 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
WO2012140519A2 (en) 2011-04-15 2012-10-18 Pluristem Ltd. Methods and systems for harvesting cells
WO2012150600A2 (en) 2011-05-04 2012-11-08 Ramot At Tel-Aviv University Ltd. Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en) 2011-05-12 2012-11-15 Rakuto Bio Technologies Ltd. Methods and device for lightening skin complexion
WO2012156976A1 (en) 2011-05-16 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of producing artemisinin in non-host plants and vectors for use in same
WO2012160526A2 (en) 2011-05-23 2012-11-29 Ofir Menashe Formulations of microorganism comprising particles and uses of same
WO2012164380A2 (en) 2011-05-31 2012-12-06 Hutchison Biofilm Medical Solutions Limited Dispersion and detachment of cell aggregates
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
WO2012172555A1 (en) 2011-06-14 2012-12-20 Yeda Research And Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A1 (en) 2011-06-23 2012-12-27 Kaiima Bio Agritech Ltd. Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
US9587010B2 (en) 2011-07-18 2017-03-07 The Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
WO2013011347A1 (en) 2011-07-18 2013-01-24 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2013011507A1 (en) 2011-07-20 2013-01-24 Kaiima Bio Agritech Ltd. Maize plants having a partially or fully multiplied genome and uses thereof
EP2550982A1 (en) 2011-07-27 2013-01-30 Technion Research & Development Foundation Ltd. Devices for surgical applications
WO2013018060A2 (en) 2011-08-04 2013-02-07 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
EP3208338A1 (en) 2011-08-04 2017-08-23 Yeda Research and Development Co., Ltd. Micro-rna mir-15 and compositions comprising same for the treatment of corticotropin-releasing hormone- associated medical conditions
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013024481A1 (en) 2011-08-14 2013-02-21 Kaiima Bio Agritech Ltd. Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013035099A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013035071A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Novel risk biomarkers for lung cancer
US9422558B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US9422557B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
US9771431B2 (en) 2011-10-11 2017-09-26 Ccam Biotherapeutics Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
WO2013054331A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013056377A1 (en) 2011-10-21 2013-04-25 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en) 2011-10-27 2013-05-02 Yeda Research And Development Co. Ltd. Method of treating cancer
WO2013067076A2 (en) 2011-11-03 2013-05-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A1 (en) 2011-11-23 2013-05-30 Danziger Dan Flower Farm Otomeria plants
WO2013076730A1 (en) 2011-11-27 2013-05-30 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis and compositions capable of same
EP3034087A1 (en) 2011-12-08 2016-06-22 Yeda Research and Development Co. Ltd. Mammalian fetal pulmonary cells and therapeutic use of same
WO2013084190A1 (en) 2011-12-08 2013-06-13 Yeda Research And Development Co. Ltd. Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A1 (en) 2011-12-20 2013-06-27 Collplant Ltd. Collagen coated synthetic polymer fibers
US9726581B2 (en) 2011-12-22 2017-08-08 Realbio Technologies Ltd. Sequential lateral flow capillary device for analyte determination
WO2013098820A1 (en) 2011-12-28 2013-07-04 Kaiima Bio Agritech Ltd. Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013098813A1 (en) 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
WO2013114373A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Inhalable liquid formulations of dnase i
WO2013114374A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013121427A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
WO2013121416A1 (en) 2012-02-14 2013-08-22 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
WO2013121405A1 (en) 2012-02-19 2013-08-22 Protalix Ltd. Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013124817A2 (en) 2012-02-22 2013-08-29 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013124816A2 (en) 2012-02-22 2013-08-29 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons
WO2013128454A1 (en) 2012-03-01 2013-09-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Male sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013132495A1 (en) 2012-03-07 2013-09-12 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1 (en) 2012-03-15 2013-09-19 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2013140247A1 (en) 2012-03-20 2013-09-26 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013140389A1 (en) 2012-03-22 2013-09-26 Ramot At Tel-Aviv University Ltd. Plif multimeric peptides and uses thereof
WO2013153553A2 (en) 2012-04-13 2013-10-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for controlling varroa mites in bees
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2013168164A1 (en) 2012-05-09 2013-11-14 Yeda Research And Development Co. Ltd. Variants of tace pro-domain as tnf-a inhibitor and their medical use
US8865158B2 (en) 2012-05-22 2014-10-21 Ramot At Tel-Aviv University Ltd. Bacteriophages for reducing toxicity of bacteria
US9290564B2 (en) 2012-05-24 2016-03-22 Mountgate Group Limited Compositions and methods related to the prevention and treatment of rabies infection
WO2013183048A1 (en) 2012-06-03 2013-12-12 Ben-Gurion University Of The Negev Research And Development Authority Functionalized titanium binding peptides and implants coated with same
US9821070B2 (en) 2012-06-04 2017-11-21 Opko Biologics Ltd. Pegylated OXM variants
WO2013183052A1 (en) 2012-06-04 2013-12-12 Prolor Biotech Inc. Pegylated oxm variants
WO2014006621A1 (en) 2012-07-03 2014-01-09 Nanospun Technologies Ltd. Methods and devices for adsorption and biodegradation of petroleum
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of